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TO ALL CHILDREN AND TEENAGERS WITH ECZEMA
Natalia Ballardini  Summary  1 
 
 
SUMMARY 
Eczema (atopic dermatitis) is a common itchy inflammatory skin disease that often starts 
in childhood. Having eczema is troublesome and has been shown to reduce quality of life. 
Eczema is associated with an increased risk for other allergy-related diseases such as 
asthma and rhinitis. Knowledge concerning the natural course of eczema and its 
association with asthma and rhinitis in childhood is limited. Even though a majority of 
children with eczema have mild disease, most studies on quality of life and associations 
with asthma and rhinitis have been done in selected populations of children with moderate 
to severe eczema. New knowledge about eczema genetics and skin barrier function has 
highlighted the need for longitudinal studies to better understand the natural course of 
eczema as well as its association with eczema, asthma and rhinitis. 
 
The aim of this epidemiological study was to provide a better understanding of childhood 
eczema in the general population and especially its association with asthma and rhinitis. 
We used the population-based birth cohort BAMSE, including 4,089 children followed up 
at age 0, 1, 2, 4, 8 and 12 years with parental questionnaires focusing on symptoms of 
allergy-related diseases and risk factors.  
 
In paper I we showed that allergy-related diseases affect a majority of children during the 
first 12 years of life and that eczema, asthma and rhinitis develop dynamically throughout 
childhood. In addition we found that comorbidity between allergy-related diseases increase 
with increasing age and that 7.5% of 12-year-old children have two or three of the diseases 
eczema, asthma and rhinitis.  
 
In paper II we examined eczema severity at 12 years in relation to asthma, rhinitis and 
Filaggrin mutations. We found that the risk of having asthma and rhinitis was associated 
with eczema severity, with the highest risk among boys with moderate to severe eczema. 
However, no association between Filaggrin mutations and severity of eczema was found.  
In paper III we showed that eczema and even mild eczema among pre-adolescent girls is 
associated with impaired self-perceived health.  
 
Finally, in paper IV we examined prognosis and risk factors for eczema, asthma and 
rhinitis in pre-adolescence among children with infantile eczema. We found that almost 
half of the children with infantile eczema will have eczema, asthma or rhinitis in pre-
adolescence but in three of four children the eczema will have remitted. We also found 
that eczema in the first but not the second year of life is associated with a good prognosis 
for eczema but an increased risk of asthma and rhinitis in pre-adolescence. 
 
In conclusion the results of this thesis stress the importance of allergy-related diseases and 
in particular eczema among children as a public health concern. This thesis also 
demonstrates a strong association between eczema, asthma and rhinitis in childhood and 
emphasizes the importance of considering comorbidities between these diseases both in 
research and in clinical practice. 
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4 PREFACE 
I have learned a lot during the work with this dissertation. When I started to write the 
thesis summary chapter I realized that most of the learning outcomes do not lie in the 
result of the studies. In my experience, the entire work process that precedes decisions on 
what to study and analyse and what ultimately to include in each separate paper has given 
me new and valuable insights.  
 
Research may appear straightforward. You have a hypothesis you want to test. You engage 
people with the competence needed and together you figure out the best and most 
efficient way to test your hypothesis. You compose a research plan describing the aim of 
the study and how it should be carried out, including how data should be collected, 
analysed and presented in the form of tables and figures. You stick to the plan without any 
deviations. You discuss the findings and what they mean with your co-authors. You write 
the paper and then you get it published.  
 
Even though the procedure described above is almost always what we strive for, I am 
quite sure it seldom happens. I assume that the human mind does not have the capacity to 
anticipate what questions or obstacles will appear along the way. My guess is that 
regardless of what efforts are made to ensure that everything has been thought of and 
planned for in the beginning of a large project, it will not be sufficient. And in the end, 
when looking back, we will probably ask ourselves, “why didn’t we think of that?”  
 
Looking back on the projects in which I have participated I wonder if the work processes 
could have been made more straightforward and effective through better planning on my 
part, and I am sure they could. However, a major lesson for me is that research is a 
creative and dynamic process where chance, deviations and detours can be essential in 
order to discover new and unexpected results. Though this is sometimes frustrating, it is 
also what makes research so intriguing.   
 
Since these insights and experiences have been valuable to me, I choose to share them, 
hoping that my reflections will illustrate both the fun and the frustration involved in 
writing a thesis. Hopefully, the framed text in this thesis called reflections can give a 
somewhat different perspective on what you learn as a PhD student. For an experienced 
scientist the reflections might seem trivial. So if you are looking for a more traditional 
reading experience, please just skip the framed sections. Regardless of how you read, I 
hope you find the reading worthwhile. 
 
Natalia Ballardini 
Stockholm 2013
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5 INTRODUCTION 
Eczema1 (atopic dermatitis) is an itchy inflammatory skin disease affecting up 
to 30% of children at some time during childhood.2 Having eczema is 
troublesome and impairs the quality of life for the affected child as well as for 
the family3 and has been shown to be associated with other allergy-related 
diseases such as asthma and rhinitis.4 Eczema, asthma and rhinitis are all 
diseases of public health concern, but knowledge regarding natural course 
and the interrelationship between these diseases is limited. Even though a 
majority of children with eczema have mild disease most studies on quality of 
life and the relation between eczema, asthma and rhinitis have been 
performed in selected populations of children with moderate to severe 
disease.4-9 Recent developments in our knowledge of eczema genetics and 
skin barrier function have highlighted the need for longitudinal studies to 
better understand the natural course of eczema as well as the association with 
other allergy-related diseases.10-12 
 
The BAMSE survey is a population-based birth cohort study initiated 1994 
with the aim of studying risk factors for allergy-related diseases.13 The papers 
in this thesis are based on material from the BAMSE study with data from 
birth up to pre-adolescence. The overall aim of this thesis is to provide a 
better understanding of eczema in the general population and especially the 
relation to asthma and rhinitis in childhood. 
 
The first paper describes development and comorbidity of eczema, asthma 
and rhinitis during the first 12 years of life. In the second paper, including 
pre-adolescent children, eczema and severity of eczema are studied in relation 
to sex, filaggrin mutations, asthma, rhinitis and topical treatment. The third 
paper focuses on the impact of eczema on quality of life and self-perceived 
health among pre-adolescent boys and girls. In the fourth paper, children 
with infantile eczema are studied with the aim to examine prognosis and to 
identify risk factors in infancy for eczema, asthma and rhinitis in pre-
adolescence.  
 
The terms allergic diseases and allergy-related diseases are not well defined. In 
this thesis they are used to refer to eczema (as defined by the WAO 
nomenclature1), asthma, rhinitis and rhinoconjunctivitis; thus allergic contact 
dermatitis among other diseases is not included.  
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6 BACKGROUND 
ALLERGIC DISEASES 
Allergic diseases exist worldwide but there are large international differences 
in prevalence.14 Over the last decades there has been a marked increase in the 
prevalence of allergic diseases15-17 globaly and 30-40% of the world 
population is estimated to be affected.18 Allergic diseases develop when the 
immune system reacts to a substance, an allergen, which is normally 
harmless.1 Most allergic reactions are caused by allergen-specific IgE-
antibodies. Common allergens are proteins in pollens, house dust mites, 
animal dander and foods.  
 
When an individual who has allergen-specific IgE antibodies (i.e. who is 
sensitized) is exposed to that specific allergen, allergic symptoms may occur. 
These symptoms may arise in a number of organs. For instance, the mucous 
membranes in the nose and eyes can be affected, leading to symptoms of 
rhinitis and conjunctivitis. If the lungs are affected symptoms of asthma 
might be triggered; in the skin, eczema or urticarial reactions may arise. 
Although eczema, asthma and rhinitis may develop as a result of IgE-
mediated allergy, these diseases also occur as diseases without any allergic 
component involved.  
  
Allergic diseases are sometimes called atopic diseases. According to the 
revised nomenclature for allergy, “atopy is a personal and/or familial 
tendency, usually in childhood or adolescence, to become sensitized and 
produce IgE antibodies in response to ordinary exposures to allergens, 
usually proteins. As a consequence, these persons can develop typical 
symptoms of asthma, rhinoconjunctivitis, or eczema”.1 Thus, an individual 
with eczema who also has rhinitis caused by IgE-antibodies to pollens has 
atopic eczema even though the specific IgE-antibodies neither cause nor 
worsen the eczema.  
 
Comorbidity between allergic diseases has mostly been investigated in 
cohorts of children who have one specific allergic disease and in high risk 
birth cohorts selected on the basis of parental allergy. Results have 
consistently shown that comorbidity is substantial4 9 19-22 and some data 
suggest that allergic comorbidity is associated with more persistent and more 
severe disease.23 24 
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In the population-based ISAAC study of 463,801 children aged 13–14 years  
from 56 countries the prevalence of symptoms of at least two of the three 
disorders eczema, asthma or allergic rhino-conjunctivitis varied from 0.3% 
to 18.5% with the highest rates in English-speaking Western countries.14  
 
Eczema, asthma and rhinitis often debuts in childhood. Data indicate that 
allergic morbidity in childhood, even though transient, is of importance for 
allergy related diseases in adulthood.25-31 The atopic march is a concept 
developed to describe the progression of allergic diseases from eczema in 
infancy to asthma and rhinitis later in life.32 
 
Atopy and allergic diseases run in families and a positive family history is a 
strong risk factor for developing allergic disease.33-35 In recent years a large 
number of genetic studies have been conducted to determine the genetic 
components of these diseases and many genes have been identified.36-39 
However, the increasing prevalence of allergic diseases cannot be explained 
by genetic factors alone and the increase – together with the large 
differences in prevalence between urban and rural regions – points towards 
environmental factors.  
 
Epidemiological research has therefore focused on identifying possible 
environmental factors associated with allergic diseases. Even though major 
efforts have been made, rather little is known about causal factors 
underlying the increase of allergic diseases over the last decades.  
 
 
ECZEMA  
Nomenclature 
The word eczema is of Greek origin (έκζεμα); the original meaning is “to boil 
over” or “thrown out by heat” and it probably refers to the acute oozing, 
vesicular eczema. The EAACI nomenclature task force proposed a new 
revised nomenclature for allergy in 200140 but it was not until some years later 
that agreement was reached within the World Allergy Organization to use the 
word dermatitis as the general term for what previously had been called 
eczema.1  
  
10 Background  Aspects of Eczema in Childhood 
 
 
The term “eczema” should be reserved for the condition also called atopic 
dermatitis, flexural eczema, constitutional neurodermatitis, eczema-asthma 
syndrome or prurigo Besnier. All other forms of  eczema should be called 
dermatitis, e.g. allergic contact dermatitis and seborrhoeic dermatitis. 
Furthermore, the WAO nomenclature allows eczema to be sub-divided into 
atopic and non-atopic eczema based on the presence or absence of  IgE-
sensitization. Consequently, testing either with IgE-antibody determination or 
skin test is required for this sub-division. 
 
Atopic eczema refers to eczema in individuals with presence of allergen-
specific IgE; non-atopic eczema refers to eczema in individuals who have 
been tested without allergen-specific IgE being detected. The term eczema 
without specification refers to eczema of unknown type or can be used as an 
umbrella-term for both atopic and non-atopic eczema.1 Even though this 
nomenclature has gained international recognition the term eczema is still 
under debate, and the term atopic dermatitis is frequently used in parallel.41 
 
Definition and diagnostic criteria  
Eczema is a pruritic, chronically relapsing inflammatory skin disease with 
typical morphology and distribution.42 Eczema is a clinical diagnosis and 
there is no definitive diagnostic "gold standard" for diagnosing eczema.43 In 
general, physicians diagnose the disease through recognition of symptoms 
and clinical features but without conscious awareness or active use of 
diagnostic criteria.  
 
However, in research, diagnostic criteria for defining cases are essential and 
ideally, the same criteria should be used worldwide, to allow comparison 
between studies.44 Also in a clinical setting, when diagnosis is not clear, 
diagnostic criteria are of great value since there is no specific diagnostic 
laboratory marker for eczema.  
 
Williams criteria45 are commonly used and are the most extensively validated 
criteria.46 47 These criteria, presented in 1994 by Williams and co-workers in 
the UK working party, was a refinement of the criteria Hanifin and Rajka 
presented in 1980.48 The aim of the UK working party was to develop criteria 
which were simple to use and suitable for epidemiological studies.  
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According to Williams the patient must have an itchy skin condition (or 
parental report of scratching or rubbing in a child). Plus 3 or more of the 
following: 
 History of involvement of the skin creases such as folds of elbows, 
behind the knees, fronts of ankles or around the neck (including 
cheeks in children under 10). 
 A personal history of asthma or hay fever (or history of atopic 
disease in a first-degree relative in children under 4). 
 A history of a general dry skin in the last year. 
 Visible flexural eczema (or eczema involving the cheeks/forehead 
and outer limbs in children under 4). 
 Onset under the age of 2 (not used if child is under 4). 
 
As indicated by Williams’s criteria it is possible to diagnose eczema in a 
child without skin symptoms at examination. However, the relapsing course 
of the disease complicates epidemiological studies and there are no accepted 
standards for how incident cases or remission should be defined.44 Many 
studies define remission of eczema as a disease-free state lasting at least 12 
consecutive months; however, definitions of remission vary.49 50 
 
Prevalence 
Eczema is very common among children in western industrialized countries 
and there has been a marked increase during the last decades.15 17 51 52 
According to Phase One of the ISAAC study, started in 1991, the 12-month 
period prevalence of eczema in children aged six or seven years ranged from 
less than 2% in Iran to around 20% in England, Australia and the 
Scandinavian countries.53 Phase Three, carried out 5-10 years later, showed an 
increase in prevalence of eczema in children aged 6-7 years in most countries. 
This was also true for children 13-14 years old in developing countries. 
However, in countries where the prevalence rates of eczema had been high 
from the start of the study, no increase was seen in the older age group.16  
 
Causes 
Eczema is a complex disease: both genetic and environmental factors are 
important in the pathogenesis. A strong genetic predisposition has been 
confirmed in twin studies showing a concordance of 0.72 for monozygotic 
and 0.23 for dizygotic twins.54  
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The genetics of eczema is complex and a large number of genes of 
importance for both adaptive and innate immunity as well as for skin barrier 
function have been identified to be associated with eczema.2 55 The strongest 
associations found are for genes encoding Filaggrin (FLG) and mutations in 
these genes lead to impaired skin barrier function and confer a genetic 
predisposition for dry skin and eczema, as well as predisposing persons with 
eczema for asthma.56-60 FLG mutations have also been associated with 
eczema severity: the disease seems to be more severe in patients who are 
FLG mutation carriers.61-64  
 
Data indicate that FLG mutations differ between populations.65 66 This might 
contribute to the nationwide variance in prevalence of eczema. However, it 
cannot explain the difference between rural and urban regions.67 68 Affluence 
and the western life-style are associated with high prevalence of eczema and 
studies in immigrants have shown that individuals who move from countries 
with low prevalence take on the higher risk of eczema in their adoptive 
country.69 These findings, together with the increased prevalence rates of 
eczema during the last decades, point towards environmental factors. 
 
In 1989, David P Strachan found that hay fever and infantile eczema were 
associated with family size and the individual’s position in the household, 
with higher risk for children who had few siblings.70 Based on his findings 
he suggested that allergic diseases might be prevented by infection in early 
childhood and that declining family size, improvements in household 
amenities, and higher standards of personal cleanliness had reduced the 
opportunity for cross-infection leading, in turn, to increased prevalence of 
atopic diseases. His findings were confirmed by others and his hypothesis 
spread rapidly under the name “the hygiene hypothesis”. Since then many 
studies have been conducted to evaluate the impact of early infections and 
microbial exposures early in life on development of allergic diseases.71 
 
In 2005 and 2011 Flohr et al reviewed studies that examined environmental 
exposures in relation to eczema and that might confirm the “hygiene 
hypothesis”.72 73 No particular childhood infection or single environmental 
pathogen was found that could explain Strachan’s findings. However, 
studies from developing nations showed that helminth infections during 
pregnancy might protect against the development of eczema in childhood.74  
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The reviews from 2005 and 2011 also found protective effects of 
consumption of unpasteurized milk, endotoxin exposure, day care during 
infancy and being brought up with a dog during early life. Broad-spectrum 
antibiotics used both during pregnancy and infancy increased the risk of 
eczema significantly. Flohr et al argued that this finding, in combination 
with studies showing protective effects of probiotics,75 makes early priming 
of the immune system via the gut mucosa a possible key factor for 
development of eczema.73 
 
A recent overview of reviews of randomized clinical trials for prevention of 
eczema in infants and children found some evidence that prebiotics as well 
as exclusive breastfeeding for at least 6 months might reduce eczema 
incidence in high-risk children. Apart from this, no effect was seen for the 
other interventions tested, including maternal antigen avoidance, omega oil 
supplementation, probiotics and different types of hypoallergenic 
formulas.76 Environmental triggers of eczema include IgE-mediated allergy, 
with foods and house dust mites as major allergens.77 78 In addition, airborne 
allergens such as pollens and dander from furred pets may also cause 
deterioration of eczema.79 80 Non-allergic triggers of eczema include sweating, 
infections, climate factors, skin irritants and emotional stress.42 80 81 
 
Clinical Features 
Most eczema cases debut in infancy and at this age the eczema is usually 
located to cheeks, head, trunk and extensor surfaces of the extremities.82 
Based on the distribution, eczema is divided into three age-related stages 
starting with the above mentioned infantile phase (0-2 years). In the 
childhood phase (3-11 years) eczema involving flexures (folds of elbows, 
behind knees, fronts of ankles, wrists and neck) predominates. The 
adolescent/young adult phase (≥12 years) resembles the childhood phase 
with the addition of involvement of the face and upper trunk.82 Characteristic 
of eczema at all ages are dry skin and dermal itch.  
 
Treatment 
The first-line treatment for eczema for patients of all ages is topical 
glucocorticoids together with emollient creams.83 Topical glucocorticoids 
have an anti-inflammatory effect, reduce itch and inflammation and should 
be used for treatment of flares but can also be used as maintenance therapy 
two or three times weekly.84 85  
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Emollients are recommended for regular use; they reduce dryness and itching 
of the skin and have been shown to reduce eczema flares.83 86 Emollient as an 
adjunctive therapy to topical glucocorticoids has also been shown to reduce 
the need of topical glucocorticoids among children with eczema to moderate 
eczema.87 Other treatments available for eczema include topical calcineurin 
inhibitors, phototherapy and systemic immunosuppressive treatments.83 88  
 
Disease severity measurement 
Many different scales are employed to measure the severity of eczema and 
severity results can differ depending on the method used.89 However, 
population-based studies consistently show that a majority of children have 
mild disease (45-84%) and only a minority have severe disease (0-13%).89-96 
Scales for evaluation of eczema severity have mainly been developed for use 
in clinical trials, to evaluate interventions and treatments.97 A review by 
Schmitt and co-workers published in 2007 declared that there are too many 
published outcome measures for eczema. Moreover, apart from SCORAD,98 
EASI,99 and POEM100 the scales had not been tested properly or did not 
perform adequately when tested.97 101  
 
The diversity of scales is a problem since it hampers scientific 
communication and makes it difficult to compare the efficacy of various 
therapeutic interventions.101 102 Some scales include only physician-oriented 
“objective” outcome measures, while others take patient-oriented outcome 
measures into account, such as patients’ or parents’ reports of itch and sleep 
disturbance. 
 
Most scales aim to assess the current disease severity by evaluating ongoing 
skin symptoms and by asking questions about subjective symptoms the 
previous week.100 101 103-105 These scales provide an estimate of the current 
disease severity and work well for evaluation of interventions. However, since 
eczema is seasonally variable79 106 and is intermittent by nature these scales fail 
to provide information of severity or disease burden over time. In contrast, 
the Nottingham Eczema Severity Score (NESS),91 based on the Rajka and 
Langeland grading,107 is a scale developed for population-based research. 
NESS assesses eczema severity during the last 12 months, even though 
disease extent is estimated based on a single evaluation. NESS has been 
validated in the age group 1-5 years, but has subsequently been used in a 
study population with a mean age of 11.7 years.108 109 
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Comorbidity  
Children with eczema have an increased risk of asthma and rhinitis.4 110 111 
Most studies addressing comorbidity have been performed in selected 
cohorts of eczema patients from specialized clinics or hospital settings. The 
association between eczema and asthma is well documented, as are the 
increased risk of asthma later in life among children with eczema.9 19 112-115  
 
In a systematic review including 13 prospective cohort studies, of which 4 
followed  birth cohorts and 9 followed eczema cohorts, van der Hulst and 
co-workers evaluated the risk that children who had eczema before age 4 
would develop asthma after age 6.116 The pooled odds ratio for the risk of 
asthma after eczema, compared with children without eczema was found to 
be 2.14 (95% CI, 1.67-2.75) in birth cohort studies. In eczema cohort studies 
the prevalence of asthma at the age of 6 years was 35.8% (95% CI, 32.2% to 
39.9%) for inpatients and 29.5% (95% CI, 28.2% to 32.7%) for outpatients, 
indicating that severity of eczema is associated with the risk of developing 
asthma.  
 
Prognosis 
In a Swedish cohort of children from a hospital-based outpatient clinic, 60% 
of children with eczema were free of disease in early adolescence.117 
However, up to 50% may have recurrences in adulthood.118 In addition to 
concomitant asthma and rhinitis, early-onset disease, severe early disease and 
a family history of eczema may predict a more persistent course of eczema.111 
Furthermore, sensitization to foods or inhalant allergens has been found to 
predict a worse prognosis for eczema with more persistent disease during 
childhood.19  
 
There are some studies indicating that FLG null mutations are associated 
with more persistent disease.119 120 For children with eczema and their parents, 
the eczema prognosis is of interest, as is the risk of future development of 
asthma or rhinitis. The associations between eczema, asthma and rhinitis are 
evident and many studies support the concept of the atopic march. However, 
whether the association between eczema in infancy and asthma and rhinitis 
later in life is causal, or not, has been under debate.10 19 113 121 122  
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Quality of life 
It is well known that eczema may affect the health related quality of life 
(HRQoL) of children with eczema as well as that of their families. Living 
with a chronic disease such as eczema may affect several dimensions of life. 
Sleep disturbance due to itching is common and it is estimated that up to 
60% of children with eczema have disturbed sleep, with numbers increasing 
to 83% during exacerbations.123 Treatment is demanding, often including 
time-consuming daily topical applications. In many cases eczema is a disease 
that shows, sometimes affecting the patient’s social life and interaction with 
others.124 
 
To measure the impact of eczema on health-related quality of life both 
disease-specific and generic instruments have been used. Disease-specific 
questionnaires investigate the areas of HRQoL considered to be most 
relevant for one particular disease or condition. These questionnaires often 
have high response rates, since directly disease-related questions are 
meaningful to the sufferers.125 One such questionnaire is the Children’s 
Dermatology Life Quality Index (CDLQI), a well validated instrument that 
has been widely used to evaluate the impact of eczema and other skin 
diseases on HRQoL.126 127 Studies using CDLQI have shown that severity of 
eczema correlates with HRQoL and have revealed greater impairment among 
children with severe eczema.5 128 129  
 
Generic instruments have the advantage of being applicable in both healthy 
and chronically ill subjects across a wide range of populations.130 131 By using 
generic instruments it has been shown that generalized childhood eczema is 
associated with impairment of quality of life of the same magnitude or even 
worse than other childhood diseases, such as epilepsy, asthma and diabetes.3 
132 A study carried out in an outpatient paediatric dermatology setting, 
reported that the quality of life among the families of children with mild 
eczema was impaired to the same degree as that of families of children with 
diabetes.133  
 
Thus, mild eczema may also have a profound impact on HRQoL. However, 
since most children with eczema are treated by general practitioners and only 
more severe cases by specialists, findings from these settings cannot be 
generalized to children with eczema in general.  
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Self-perceived health is often used in health studies that examine the physical 
and mental health of children and teenagers, such as the WHO collaborative 
cross-national study.134 By asking a simple question such as “How are you 
feeling?” an overall assessment of health, both mental and physical, is obtained.  
Self-perceived health has been shown to correlate well with objective 
measures of physical health status and also with psychological health; for 
example, adolescents suffering from depression report lower self-perceived 
health than others.135-137  When assessing the impact of eczema on HRQoL 
using a generic instrument or self-perceived health it is important to take 
comorbidity into account so that the results are not confounded by 
concomitant asthma or rhinitis.  
 
 
EPIDEMIOLOGY 
Epidemiology can simply be described as “the study of the occurrence of 
illness”.138 There are two main measures of disease occurrence: prevalence 
and incidence. Prevalence describes the proportion of people in a population 
who have a disease at a specific time and reflects both disease duration and 
incidence. Incidence, on the other hand, describes the number of people in a 
population that go from being healthy to having a disease over a specified 
period of time. Thus, calculating incidence require longitudinal studies, such 
as cohort studies, while prevalence can be measured at one time point as is 
done in cross-sectional studies.  
 
Prevalence is commonly used in areas of public health since it measures the 
disease burden in a population. However, in studies of preventive measures 
or in research on causation, incidence measures are more appropriate. For 
diseases with insidious onset and diseases with a fluctuant course it may be 
difficult to define onset.44 It is therefore sometimes necessary to describe 
these conditions in terms of prevalence rather than incidence. For allergic 
diseases, measures of “period prevalence” are commonly used.139 A 12-
month period prevalence refers to the proportion within a population that 
had a disease at any time during a period of 12 months. Another type of 
period prevalence is lifetime prevalence, which refers to the proportion who 
had the disease at any time in life. Various errors that may occur in 
epidemiological research are elaborated on in the Discussion section of this 
thesis.    
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7 AIMS 
The overall aim was to provide a better understanding of childhood eczema 
in the general population and especially the relation to asthma and rhinitis.  
 
The specific objectives were: 
 
To study development of eczema, asthma and rhinitis in relation to sex and 
parental allergy throughout childhood, in a population-based cohort. 
 
To investigate eczema severity in relation to sex, FLG mutations, topical 
treatment, asthma and rhinitis among pre-adolescents. 
 
To assess the impact of eczema for quality of life among pre-adolescent 
children in a population-based cohort, taking both eczema severity and 
comorbidity into account.  
 
To examine prognosis of eczema and risk factors for eczema, asthma and 
rhinitis in pre-adolescence among children with infantile eczema.  
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8 MATERIAL AND METHODS 
STUDY SUBJECTS 
The BAMSE project 
All papers in this thesis are based on material from the BAMSE cohort. The 
BAMSE project is a longitudinal population-based cohort in which children 
have been prospectively followed during childhood and early adolescence. 
The abbreviation “BAMSE” is a Swedish acronym that stands for “Barn, 
Allergi, Miljö i Stockholm en Epidemiologisk studie”. The English translation 
reads “Children, Allergy, Milieu, Stockholm, Epidemiological Study”. The 
main aim of the BAMSE study was to establish risk factors for development 
of allergy-related diseases in childhood. The original plan was to follow the 
children up to the age of four years, but most of the cohort have now been 
followed well into their teens. 
 
Recruitment  
Parents of all children born between 1994 and 1996 living in predefined areas 
of the central and north-western parts of Stockholm were asked to 
participate. The areas were chosen to represent both urban and suburban 
environments with a representative mix of housing and socio-economy. A 
community population register made it possible to reach the parents of 
infants born in the areas during the study period.13 Figure 1 shows a flow 
chart of the study with included and excluded children. Of the 7,221 children 
born in the recruitment area during the study period, 477 could not be 
reached and 1,256 were actively excluded, leaving 5,488 eligible subjects 
(Figure 1). 
 
The BAMSE cohort 
The study base of the BAMSE cohort comprised 4,089 infants, 
corresponding to 75% of the eligible subjects. Detailed data on residential 
characteristics, environmental factors and parental allergy were obtained from 
a baseline parental questionnaire when the infant was two months old. Non-
responders and actively excluded families were contacted in 1996 with a short 
questionnaire on key exposures and parental allergy.13 Response rates were 
58% and 83%, respectively.  
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In this group of non-responders and actively excluded families, smoking was 
significantly more common. However, other background factors including 
parental allergy did not differ when included families were compared with 
non-responders and excluded families.  
 
 
 
Figure 1. Description of the BAMSE birth cohort. Yellow fields in the lower section 
represent periods of data collection. 
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Follow-ups 
When the 4,089 children in the cohort reached the ages of one, two, four and 
eight years, the parents received questionnaires focusing on symptoms of 
eczema, asthma and rhinitis, life style factors and key exposures. The 
response rates were 96%, 94%, 91% and 84% respectively. For the 12-year 
follow-up, all questionnaires were sent out on one occasion in springtime 
2008. The children were then between eleven and fourteen years old (mean 
age 12.9 years).  
 
At the 12-year follow-up, both the parent and the child were asked to 
participate. Parents and children completed one questionnaire each, intended 
to collect information about symptoms related to eczema, asthma, rhinitis, 
life style factors and key exposures. The response rate among parents was 
82% at the 12-year follow-up. The children, of whom 2,801 (69%) completed 
the questionnaire, also answered questions for evaluation of self-perceived 
general health. Children with skin symptoms during the last week were in 
addition asked to answer a disease-specific questionnaire for evaluation of 
quality of life.  
 
As part of a nested case-control study140 during 1995 to1996, 137 children 
from the BAMSE cohort with infantile eczema provided blood at two years 
for analyses of allergen-specific IgE against foods and airborne allergens. 
 
 
STUDY POPULATIONS STUDY I-IV 
The study populations for paper I-IV are derived from the BAMSE cohort, 
but differ somewhat between the studies as described below. Data collection 
for the 16-year follow-up was ongoing when the studies in this thesis were 
performed. Thus only data up until the 12-year follow-up have been used. 
Figure 2 illustrates the origin of the follow-up data used for the studies in this 
thesis. 
 
Reflection – study population 
In studies like the the ones I have been involved in, there is always a trade-off between 
wanting to have a large study population and having to handle missing data. In my 
experience a lot of work can be saved if you are thorough when thinking through and 
discussing what study population to use. This is best done early in the process with all co-
authors involved. 
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For study I we included 2,916 children (71% of the original cohort) who had 
participated at the follow-ups at age 1, 2, 4, 8 and 12 and had provided 
complete data on i) parental allergy at baseline and ii) eczema, asthma and 
rhinitis symptoms at every follow-up (Figure 2). 
 
Study II included 3,301 children (81% of the original cohort) from the 12-
year follow-up with complete data on parentally reported eczema, asthma, 
and rhinitis symptoms. DNA collected at 4 or 8 years was available for 1,854 
individuals (Figure 2).  
 
For study III the study population consisted of 2,756 children (67% of the 
original cohort) who had completed the 12-year child questionnaire with 
parentally reported data about eczema symptoms during the last year (Figure 
2).  
 
Study IV included 3,208 children (78% of the original cohort) who had 
participated at the 1-, 2- and 12-year follow-up with complete data on 
parentally reported eczema symptoms from all three follow-ups (Figure 2). 
 
 
 
Figure 2. Origin of data used for paper I, II, III and IV. Narrow symbols signify that 
relatively little data have been used from these follow ups. 
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DEFINITIONS OF BACKGROUND VARIABLES (I- IV) 
Background variables used in study I-IV are defined in table I. In study I and 
III tobacco smoke exposure (defined as maternal smoking) was used for 
comparison of the study population and the original cohort. In study IV 
tobacco smoke exposure was assessed as a risk factor for eczema, asthma and 
rhinitis in pre-adolescence among children with infantile eczema. In this 
study, based on previous publications, we used a variable that also included 
paternal smoking at the time of inclusion.141 
 
Table I Definitions of background variables used in study I-IV 
Variables Definition (based on data collected at Q0, Q1)* Paper 
Parental 
allergy 
Mother and/or father with doctor’s diagnosis of asthma and asthma 
medication and/or doctor diagnosed hay fever in combination with allergy 
to furred pets and/or pollen and/or doctor’s diagnosis of eczema at the 
time of enrolment. (Q0) 
I, II, 
III, 
IV 
Low socio-
economic 
status 
Both parents are blue collar workers according to the Nordic standard 
occupational classification and Swedish socio-economic classification.142 
(Q0) 
I, II, 
IV 
Young 
mother 
Maternal age ≤ 25 years at birth of the child. (Q0) I 
Exclusive 
breastfeeding 
≥4 months 
Exclusive breastfeeding during the first four months of life without 
exposure to formula (cow’s milk or hydrolysate) or solid foods.143 (Q1) 
I, II, 
IV 
Tobacco 
exposure 
Mother smoked at least one cigarette per day during pregnancy or at the 
time of enrolment. (Q1) 
 
I, II 
Tobacco 
smoking 
Mother smoked at least one cigarette per day during pregnancy and/or 
any of the parents smoked at least one cigarette per day at the time of 
enrolment. (Q0, Q1) 
IV 
*See Figure 2, page 22 
 
 
DEFINITIONS OF HEALTH OUTCOMES (I- IV) 
Health outcome variables for study I-IV are defined in table II. In study I, 
variables reflecting a 12-month period prevalence were used. Owing to the 
way the questionnaires had been constructed it was not possible to calculate a 
12-month period prevalence for allergic rhinitis. Instead, we used a rhinitis 
definition which we derived from the ISAAC study which made it possible to 
evaluate a 12-month period prevalence (Table II). In study II, III and IV a 
variable for allergic rhinitis was used (Table II and Table IV). 
 
24 Material and methods  Aspects of Eczema in Childhood 
 
 
 
 
 
Table II. Definitions of health outcomes used in study I-IV 
Variables Definition (based on data collected at Q1, Q2, Q4, Q8, Q12)* Paper 
Eczema at 
one year 
Dry skin, itchy rashes for two weeks or more and specific location of rash 
(face or outer aspect of arms/legs or flexures of knees/elbow or 
wrists/front of ankles) and/or doctor’s diagnosis of eczema after three 
months and up to one year of age. (Q1) 
I, IV 
Eczema at 
two years 
Dry skin, itchy rashes for two weeks or more and specific location of rash 
(face or outer aspect of arms/legs or flexures of knees/elbow or 
wrists/front of ankles) and/or doctor’s diagnosis of eczema after one 
year and up to two years of age. (Q2) 
I, IV 
Eczema at 
four years 
Dry skin, itchy rashes for two weeks or more and specific location of rash 
(face or outer aspect of arms/legs or flexures of knees/elbow or 
wrists/front of ankles) and/or doctor’s diagnosis of eczema after two 
year and up to four years of age. (Q4) 
I 
Eczema at 
eight years 
Dry skin, itchy rashes for two weeks or more and specific location of rash 
(face or flexures of arms/legs or wrists/front of ankles or neck) and/or 
doctor’s diagnosis of eczema from the age of seven years. (Q8) 
I 
Eczema at 
the 12-year 
follow-up 
Dry skin and itchy rash and specific location of rash (flexures of 
arms/legs or wrists/front of ankles or neck) in the last 12 months and/or 
doctor’s diagnosis of eczema from the age of 10 years. (Q12) 
I, II, 
III, IV 
Asthma at 
one year  
At least three episodes of wheeze between three months and 1 year of 
age in combination with inhaled steroids and/or signs of hyper-reactivity 
without concurrent upper respiratory infection. (Q1) 
I, IV 
Asthma at 
two years  
At least three episodes of wheeze between 1 year and 2 years of age, in 
combination with inhaled steroids and/or signs of hyper-reactivity 
without concurrent upper respiratory infection. (Q2) 
I, IV 
Asthma at 
four, eight 
and 12 years 
At least four episodes of wheeze in the last 12 months or at least 1 
episode of wheeze in the last 12 months in combination with occasional 
or regular use of prescribed inhaled steroids. (Q4, Q8, Q12) 
I, II, 
III, IV 
Rhinitis at 
one and two 
years  
ISAAC-rhinitis; prolonged rhinitis symptoms two months or more in the 
past 12 months. (Q1, Q2) 
I 
Rhinitis at 
four, eight 
and 12 years 
ISAAC-rhinitis; prolonged rhinitis without common cold in the past 12 
months. (Q4, Q8, Q12) 
I 
Rhinitis at 
the 12 year 
follow-up  
Symptoms from eyes/nose (suspected or evident) after exposure to 
furred pets and/or pollen and/or doctor’s diagnosis of allergic rhinitis 
from the age of 10 years. (Q12)  
II, III, 
IV 
*See Figure 2, page 22 
  
Natalia Ballardini  Material and methods 25 
 
 
EVALUATION OF ECZEMA SEVERITY (II, III) 
The questionnaire used for the BAMSE 12-year follow-up was more 
comprehensive concerning eczema than at earlier follow-ups. Questions 
modified from the Rajka and Langeland index107 for evaluation of eczema 
severity had been included. In study II a BAMSE Eczema Severity Score 
(BESS), scale 3-14, was constructed based on the responses to three 
questions: number of months with eczema during the last year, disturbed 
sleep, and number of affected body sites (multiple choice alternatives: face, 
scalp, ears, arms and/or legs, armpits, knees and/or elbows, wrist and/or 
ankles, hands, feet, throat and/or neck, buttocks, chest and/or abdomen 
and/or back and/or shoulders, groin and/or genitals).  
 
After having collected the data we discovered that the questions in BAMSE 
were very similar to the questions used for the Nottingham Eczema Severity 
Score (NESS).91 We therefore used NESS as a template for BESS. Children 
were divided into three groups on the basis of their score: mild (BESS 3-7), 
moderate (BESS 8-10) and severe eczema (BESS 11-14).  
 
Reflection – BESS versus modified NESS 
When planning for study II, I tried to figure out how to evaluate eczema disease severity 
based on the questionnaire data from the 12-year follow-up. I searched the literature to 
find out how others had done and came across NESS. The scientists who constructed 
NESS had, like us, asked questions based on the Rajka and Langeland index. I was very 
disappointed when I realized that we could not compute NESS with the data we had. I did 
an evaluation based on the questions we had and decided to use our data in such a way 
that our evaluation would be as close as possible to NESS. When I did the calculations I 
was excited to find that the proportions of mild, moderate and severe cases of eczema in 
our material were similar to the proportions in the validation study of NESS. I came up 
with the idea of calling our modified NESS-scale “BESS”. My co-supervisor Magnus 
Wickman immediately came up with a number of possible sentences that would generate 
the acronym “Porgy”. After a while we got back to work and decided to call our scale 
BESS instead of modified NESS. As argued in the background section of this thesis, there 
is really no need for yet another scale for evaluation of eczema severity. Thus, our 
approach might be considered inappropriate. However, I think we all felt satisfied with a 
scale of our own and furthermore BESS sounds much better than modified NESS. I am 
sure that BESS will be useful for future papers from the BAMSE project, but vanity is 
probably one of the reasons why it is so difficult to achieve consensus, even in the world 
of research. 
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GENOTYPING FOR FILAGGRIN MUTATIONS (II) 
DNA from blood samples collected at the 4- or 8-year follow-up was 
available for 1,854 of 3,301 children in study II. Genotyping was performed 
for the FLG mutations that are most common in Scandinavia (R501X, 
R2447X and 2282del4).59 Children with any of these mutations were classified 
as mutation carriers. 
 
ASSESSMENT OF SELF-PERCEIVED HEALTH (III) 
In the 12-year follow-up, three questions for evaluation of self-perceived 
health were included in the child questionnaire (Table III).  
 
Table III. Questions concerning self-perceived general health144 145 
Question  Response alternatives 
How are you feeling?  Excellent / very good / good / fairly good / not good 
How healthy do you 
consider yourself to be? 
Completely healthy / fairly healthy / not very healthy 
How happy are you with 
your life right now? 
I am very happy / I am fairly happy / I am not very happy / 
I am not happy at all 
 
 
ASSESSMENT OF DISEASE-SPECIFIC QUALITY OF LIFE (III) 
At the 12-year follow-up children with itchy rash in the preceding seven days 
were asked to answer the “Children’s Dermatology Life Quality Index 
(CDLQI)” questionnaire in order to collect information on the impact of 
disease on health-related HRQoL. The CDLQI includes ten questions, each 
scoring 0-3, giving a maximum of 30; the higher the score, the more negative 
effect on the HRQoL.  
 
 
DEFINITIONS OF RISK FACTORS IN STUDY IV 
Among children with infantile eczema, the following exposures were 
evaluated as risk factors for the outcomes eczema, asthma and rhinitis at 
twelve years: sex, parental allergy, tobacco exposure, asthma before two years 
of age, rhinitis before two years of age, sleep disturbance due to itch, 
persistent eczema and widespread eczema in the first two years of life. For 
definitions see Table I and Table IV.  
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Table IV. Definitions of risk factors in paper IV 
Risk factors Definition (based on data collected at Q1, Q2)* 
Asthma before 2 
years of age 
At least three episodes of wheeze between three months and 1 year of age, and/or 
between 1 year and 2 years of age, in combination with inhaled steroids and/or signs 
of hyper-reactivity without concurrent upper respiratory infection. (Q1, Q2) 
Rhinitis before 2 
years of age 
Symptoms from eyes/nose (suspected or evident) after exposure to furred pets and/or 
pollen and/or doctor’s diagnosis of allergic rhinitis sometime between 3 months and 1 
year of age, and/or  between 1 year and 2 years of years of age. (Q1, Q2) 
Sleep disturbance 
due to itch 
Reported sleep disturbance due to itch, before 2 years of age. (Q1, Q2) 
Persistent infantile 
eczema 
Having fulfilled the eczema definition in both the first and second years of life. (Q1, 
Q2) 
Widespread 
infantile eczema 
Defined as more than 5 body sites affected by eczema before 1 year of age and/or 
between 1 and 2 years of age. Sites (multiple choice alternatives): face, scalp, ears, arms 
and/or legs, armpits, knees and/or elbows, wrist and/or ankles, hands, feet, throat 
and/or neck, buttocks, chest and/or abdomen and/or back and/or shoulders, groin 
and/or genitals. (Q1, Q2) 
Atopic infantile 
eczema 
Defined as positive fx5® (allergen-specific IgE≥0.35kUA/L) and /or positive 
Phadiatop® (allergen-specific IgE≥0.35kUA/L). Sera collected at 2 years of age were 
analysed for IgE antibodies to a mix of common inhalant allergens with Phadiatop® 
(cat, dog, horse, birch, timothy, mugwort, Dermatophagoides pteronyssinus and Cladosporium 
herbarum) and to a mix of common food allergens with fx5 (milk, egg, cod, soy, peanut 
and wheat) by using the ImmunoCAP System (Thermo Fisher Scientific, Uppsala, 
Sweden). 
*See Figure 2, page 22 
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STATISTICAL METHODS 
All statistical analyses were performed with STATA Statistical Software 
(release 11.1; StataCorp, College Station, Texas, USA). 
 
Confidence intervals (I, II, III, IV) 
For evaluation of differences concerning background factors and prevalence 
of disease between the original cohort and children in the study populations, 
proportions with 95% confidence intervals (95% CI) were calculated. 
Intervals that did not overlap were considered significantly different. 
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Chi2-tests (I, II, III, IV) 
For comparison between groups for dichotomous variables χ2-tests were 
used.  
 
Wilcoxon Rank Sum test (I, II, III) 
For evaluation of differences between groups for categorical outcomes 
Wilcoxon Rank Sum test was used. 
 
Spearman correlation test (III) 
To test the correlation between eczema severity and disease-specific health-
related quality of life (CDLQI), and to test the correlation between CDQLI 
and self-perceived health, we used Spearman correlation test. 
 
Logistic regression (III, IV) 
Logistic regression was used in study III (for evaluation of the association 
between eczema, asthma, rhinitis and self-perceived health) and study IV (for 
evaluation of the association between infantile eczema and the outcomes at 
age twelve). In both studies univariate analysis was done to identify factors 
associated with the outcomes. Potential confounders were tested using 
backwards selection. Covariates that changed the β-coefficient more than 
10% for any of the tested variables were considered confounders. In study 
III, concurrent asthma, rhinitis and eczema were kept a priori for all analyses. 
Sex and parental allergy were kept a priori for all analyses in study IV. 
Covariates that were significantly associated with any of the outcomes in the 
unadjusted model were kept in the final model. Effect modification by sex 
and parental allergy was also tested in both study III and IV. Sex was found 
to be an effect modifier for the association between eczema and self-
perceived health and accordingly the analysis in study III was stratified by sex. 
 
Generalized estimated equations (I) 
Generalized estimated equations146 with an unstructured correlation matrix 
were used to assess the impact of parental allergy and sex on development of 
any allergy-related disease over time in paper I and also for eczema in the 
thesis summary chapter. The model incorporated an interaction between time 
and exposure to evaluate the effect of exposure over time. The models were 
adjusted for exclusive breastfeeding ≥4 months, maternal smoking, low 
socio-economic status and young mother (≤ 26 years). 
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Absolute risk (IV) 
Absolute risks in study IV were calculated as the number of children having 
both the outcome and the risk factor, divided by the total number of children 
with the risk factor. For 95% confidence intervals the binomial test of 
statistical significance was used.  
 
 
 
 
 
Reflection – what is the value of  a high odds ratio? 
Measuring illness is a fundamental feature of epidemiology. By comparing disease 
occurrence in groups of people that are exposed to a factor with occurrence in groups not 
exposed, knowledge has been gained about the causes of various diseases. When 
comparing disease occurrence, both absolute and relative measures can be used. Most 
people, including researchers, are insensitive to variations of risk among small 
probabilities.147 To exemplify, a healthy young smoker who is informed that the absolute 
risk of developing cancer within 10 years is 0.001% for people who continue to smoke 
compared to 0.00001% for people who stop smoking, will probably consider both risks as 
quite low. However, if confronted with the relative risk instead, being informed that the 
risk of getting cancer is 100 times higher if she continues to smoke compared to if she 
quits, she will probably think differently. The odds ratio is another way of expressing the 
relative risk and for small risks the odds ratio equals the risk ratio;138 thus the odds ratio for 
smoking on the risk of developing cancer in the above example is 100. However, the same 
absolute effect will result in a high relative risk if the disease is rare and a lower relative risk 
if it is a prevalent disease.148 In my experience, this is not intuitively understood. Thus, 
when it comes to allergy-related diseases, which are all common, the use of relative risk 
measures can make risks appear deceptively small even when the absolute risk difference 
conferred by the factor being studied is high. 
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9 RESULTS 
DEVELOPMENT OF ALLERGY-RELATED DISEASES TO AGE 12 (I) 
Up to pre-adolescence 58% of the 2,916 children with complete data on 
eczema, asthma and rhinitis who were included in study I had had eczema, 
asthma and/or rhinitis (Figure 3a). Included children did not differ from the 
original cohort (N=4,089) in terms of risk factors for development of allergy-
related diseases (Table V). 
 
 
Table V. Distribution of risk factors for allergy-related diseases in the 
study population of paper I compared to the original cohort 
    
  Variable* Original cohort   Study population 
Data collected at enrolment  N=4,089 (100%)   n=2,916 (71.3%) 
    n % 95% CI   n % 95% CI 
 
Sex 
       
     Male 2065/4089 50.5 49.0–52.0   1488/2916 51.0 49.2–52.8 
 
Parental allergy† 
       
     either or both 1746/4045 43.2 41.6–44.7   1291/2916 44.3 42.5–46.1 
 
Maternal age 
       
     < 25 years 319/4088 7.8 7.0–8.6   196/2915 6.7 5.8–7.6 
 
Socioeconomic status 
       
     blue collar workers 695/4018 17.3 16.1–18.5   431/2882 15.0 13.7–16.3 
 
Maternal tobacco smokingǂ 
       
     Yes 563/4086 13.8 12.7–14.8   346/2916 11.9 10.7–13.0 
         
Data collected at 1 year n=3,925 (96%)   n=2,916 (71.3%) 
    n % 95% CI   n % 95% CI 
 
Exclusive breastfeeding ≥4 months 
      
     No 803/3919 20.5 19.2–21.8   543/2912 18.7 17.2–20.1 
         
*Internal missing 0–1.7%  
       
†Doctor’s diagnosis of asthma and/or hay fever in combination with allergy to furred pets and/or 
   pollen and/or doctor’s diagnosis of eczema at enrolment 
  
ǂMother smoked at least one cigarette per day during pregnancy and/or at the time of enrolment 
 
Furthermore, we found no differences when comparing prevalence rates of 
eczema, asthma and rhinitis of children in the study population with children 
in the study base (Table VI). Twenty-two percent (629 of 2,916) of all 
children had had one disease at only one follow-up, while 36% (1,066 of 
2,916) either had one disease at more than one follow-up, or two or more of 
eczema, asthma and rhinitis during the study period.  
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Among children with parental allergy, 66% (858 of 1,291) had an allergy-
related disease before 12 years of age, compared to 52% (837 of 1,625) of 
children with no parental allergy, p<0.001. Boys had a lifetime prevalence of 
any allergy related disease of 60% (892 of 1,488) up to 12 years and the 
corresponding proportion for girls was 56% (803 of 1,428), p=0.042. This 
difference was mainly explained by higher prevalence rates of asthma and 
rhinitis among boys. 
 
 
 
Table VI.  Twelve-month prevalence rates of allergy-related diseases 
in the study population of paper I compared to the study base 
                  
Variable 
Original cohort (4,089) 
  
Study population (2,916) 
            
1 year N %  95% CI    n % 95% CI  
Eczema 594/3923 15.1 14.0–16.3   440/2916 15.1 13.8–16.4 
Asthma 151/3924 3.9 3.2–4.5   101/2916 3.5 2.8–4.1 
Rhinitis 145/3920 3.7 3.1–4.3   103/2916 3.5 3.1–4.3 
                
2 years N %  95% CI    n % 95% CI  
Eczema 730/3839 19.0 17.8–20.3   542/2916 18.6 17.2–20.0 
Asthma 219/3835 5.7 5.0–6.4   157/2916 5.4 4.6–6.2 
Rhinitis 154/3840 4.0 3.4–4.6   112/2916 3.8 3.1–4.5 
                
4 years N % 95% CI    n %  95% CI 
Eczema 729/3721 19.6 18.3–20.9   546/2916 18.7 17.3–20.1 
Asthma 260/3704 7.0 6.2–7.8   182/2916 6.2 5.4–7.1 
Rhinitis 413/3685 11.2 10.2–12.2   314/2916 10.8 9.6–11.9 
                
8 years N % 95% CI    n % 95% CI  
Eczema 428/3397 12.6 11.5–13.7   355/2916 12.2 11.0–13.4 
Asthma 215/3397 6.3 5.5–7.1   177/2916 6.1 5.2–6.9 
Rhinitis 462/3409 13.6 12.4–14.7   380/2916 13.0 11.8–14.3 
                
12 years N % 95% CI    n % 95% CI  
Eczema 399/3353 11.9 10.8–13.0   339/2916 11.6 10.5–12.8 
Asthma 221/3339 6.6 5.8–7.5   189/2916 6.5 5.6–7.4 
Rhinitis 693/3337 20.8 19.4–22.1   601/2916 20.6 19.1–22.1 
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Disease turnover and persistence 
Disease turnover was substantial, with a large number of new and remitting 
cases throughout the study period (Figure 3b). The average proportion of 
new cases of the diseases studied over all observational time points was 53%. 
The corresponding proportion for total remission, defined as not having the 
disease again at any subsequent follow-up, was 44%. 
 
Figure 3b also shows the proportions of children who had had i) eczema, ii) 
asthma and iii) rhinitis at one, two or three or more follow-up occasions up 
to 12 years of age. The pattern of onset and remission for eczema, asthma 
and rhinitis was similar among children with and without parental allergy, as 
well as among boys and girls. Children with parental allergy had more 
persistent eczema, asthma and rhinitis than children without parental allergy, 
all p<0.001. Boys and girls did not differ in terms of disease persistence. 
 
 
 
 
 
 
 
Reflection – trying to give the whole picture 
In study I we made every effort to find a way to illustrate development of allergy-related 
diseases in childhood. I had a vision of a graph which would explain it all. The problem 
was that I didn’t know what it would look like. I made one graph after another and they 
were all too complicated and impossible to understand. Others had created nice 
illustrations showing the development and course of one disease over time19 149 150 but I 
could not find anything similar to what I wanted to do. I finally asked myself how many 
possible phenotypes there could be in study I. It was easily calculated: three diseases and 
five follow-ups results in 32,768 possible “phenotypes”. For comparison, one disease and 
four follow-ups gives 16 possible “phenotypes”. At that point I gave up the idea of a single 
graph that would explain it all. However, I believe that Figure 3a together with Figure 3b 
will give you a fairly good notion of the dynamics of eczema, asthma and rhinitis in 
childhood even if they fail to provide any information whatsoever of the interrelationship 
between the diseases.   
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Figure 3a. Twelve-month prevalence rates of eczema, asthma, rhinitis and any of 
these diseases at age 1, 2, 4, 8, and 12 years. Empty bars show the percentage of 
children who had been affected at some follow-up before 12 years, n=2,916. 
Figure 3b. Disease turnover indicates the percentage in the population (n=2,916) of 
new and remitting cases at each observation. New cases were defined as onset of 
disease which had not been present at any previous observation and remission was 
defined as not having a disease that had been present at the previous observation. 
Persistence indicates the proportion of children who had a disease at one, two or 
three or more observation timepoints among the children who had ever had the 
same disease. 
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Development of eczema to age 12  
As shown in figure 3a 1,100 (38%) of the 2,916 children had eczema at some 
time during the study period. Among these, more than a quarter had eczema 
at three or more follow-up occasions. Thus, in the whole study population of 
2,916 children, 11% had eczema at three or more follow-up occasions. 
 
 
ADDITIONAL RESULTS - DEVELOPMENT OF ECZEMA TO AGE 12  
Only 45 of the 1,100 children with eczema had eczema at all five follow-ups. 
Figure 4 provides detailed information on the course of eczema among the 
1,100 children in the study population of paper I who had eczema at any time 
up to 12 years of age. Note that 66% (725/1,100) had onset of eczema before 
the age of two years. 
 
 
Figure 4. Course of eczema up to age 12 years in the BAMSE birth cohort n=2,916. 
Each row contains 100 rectangles, representing the 1,100 children in study I who 
had eczema at any of the one, two, four, eight and 12-year follow-ups. The course 
of each 1/100 subsample can be traced vertically. Each red rectangle represents 
subjects with eczema in the respective time period.  
 
Generalized estimated equations were used to evaluate the impact of parental 
allergy on development of eczema up to 12 years. After adjustment for 
known confounders the overall OR was 1.76 (95% CI, 1.43-2.16). As shown 
in Figure 5 the impact of parental allergy on the risk of having eczema was 
similar the first 12 years of life.  
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Male sex was associated with an increased risk (adjusted OR 1.25, 95% CI 
1.02-1.54) of eczema at age one but with a significantly reduced risk (adjusted 
OR 0.62, 95% CI 0.49-0.78) of eczema at 12 years (Figure 5). 
 
 
Figure 5. Parental allergy and sex in relation to eczema up to 12 years in the 
population-based BAMSE birth cohort, n=2,916.  
* Odds ratios and 95% confidence intervals were calculated by using generalized 
estimated equations, adjusted for: exclusive breastfeeding <4 months, maternal 
smoking, low socio-economic status and young mother (< 26 years).  
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ECZEMA SEVERITY (II) 
At twelve years, disease severity was evaluated based on questionnaire data 
including information on clinical course, disease intensity and extent of 
disease the previous year. Of the 394 children with eczema in paper II, 79% 
had mild disease, 17% moderate and only 4% had severe eczema (Figure 6). 
There was no significant difference in eczema severity between boys and 
girls. However, boys had a somewhat higher mean BESS (5.9; 95% CI 5.5-
6.3) compared with girls (5.5; 95% CI 5.2-5.7). 
 
 
Figure 6. Severity of eczema evaluated as BAMSE Eczema Severity Score (BESS) 
among pre-adolescent girls and boys in the BAMSE birth cohort. 
 
 
 
FLG MUTATIONS (II) 
FLG mutations were found in 7.3% (136 of 1.854) of genotyped children 
included in study II, all heterozygotes with two children being compound 
heterozygotes (Table VII). At the 12-year follow-up 13% (32 of 246) of the 
children with eczema and 6.5% (104 of 1,608) of children without eczema 
had at least one FLG mutation (p<0.001).  
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FLG mutations in relation to eczema severity (II) 
FLG mutations were present in 26 of 198 pre-adolescent children with mild 
eczema and in 6 of 48 children with moderate to severe eczema (13.1% vs 
12.5%, p=0.907). One child with mild eczema and one child with moderate 
to severe eczema were compound heterozygotes (Table VII).  
 
Table VII. Type of FLG mutation in relation to eczema status among 
1,854 genotyped children in the population-based BAMSE birth cohort 
FLG mutation* 
No eczema 
n=1,608 
n (%) 
Mild eczema 
n= 198 
n (%) 
Moderate-to- 
severe eczema 
n=48 
n (%) 
Total 
n=1,854 
n (%) 
R501X 28 (1.7) 11 (5.6) 2 (4.2) 41 (2.2) 
2282del4 62 (3.9) 11 (5.6) 5 (10.4) 78 (4.2) 
R2447X 14 (0.9) 5 (2.5) 0 19 (1.0) 
Total 104 (6.5) 26 (13.1) 6 (12.5) 136 (7.3) 
* Two children were compound heterozygotes; a girl with mild eczema (2282del4 and 
R2447X) and a boy with moderate to severe eczema (R501X and 2282del4). No child was 
homozygote for any FLG mutation. 
 
 
 
 
 
 
Reflection - how to please reviewers 
For paper I we had decided to do a descriptive study without a hypothesis but with the 
aim of describing development of allergy-related diseases in childhood, and we did. 
However, the reviewers wanted us to go beyond descriptive analysis; they wanted 
longitudinal analyses as well as evaluation of different phenotypes and predictors for 
subsequent disease development. We agreed that this could be interesting, but that it 
would be a totally different study. In order to please the reviewers we analysed the impact 
of sex and parental allergy on the risk of developing any allergy-related disease at different 
ages. This was doable without having to rewrite the whole paper. But as pointed out to us 
after the paper had been published, it is not very logical to evaluate the impact of sex on 
any disease, since we know the impact is not the same for eczema, asthma or rhinitis. I 
guess that at the end of the review process, things slip through that normally would not 
pass, because everyone is tired of the manuscript and just wants it to move on. In the 
summary of my thesis these results have not been included. Instead, I chose to present the 
corresponding calculations for eczema as shown in Figure 5.  
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COMORBIDITY OF ALLERGY RELATED DISEASES (I) 
The overlaps between eczema, asthma and rhinitis at the different follow-ups 
are illustrated in Figure 7. Comorbidity became more prevalent with age. At 
least two allergy-related diseases were found in 1.8% of children at one year 
of age. At two, four, eight, and 12 years the corresponding proportions were 
2.3%, 5.9%, 5.5%, and 7.5%. Among children who had an allergy-related 
disease, allergic comorbidity was more prevalent among those whose parents 
had allergy. Differences in comorbidity between boys and girls were minor. 
 
 
Figure 7. Comorbidity of eczema, asthma and rhinitis up to 12 years of age in the 
population-based BAMSE birth cohort, n=2,916. Venn diagrams are proportional. 
 
 
Comorbidity among children with eczema (I, II) 
Asthma and/or rhinitis were present among 9.8% of children with eczema at 
one year of age. At two, four, eight, and 12 years the corresponding 
proportions were 10.1%, 26.2%, 31.0%, and 42.2% (Figure 7). In paper II we 
evaluated comorbidity in relation to sex and eczema severity in pre-
adolescence. We found that among children with moderate to severe eczema, 
rhinitis was significantly more prevalent (45.1% vs 32.7%, p=0.036) and 
asthma tended to be more prevalent (22.0% vs 13.8%, p=0.069) than among 
children with mild eczema. Also, the combination of asthma and rhinitis was 
significantly more prevalent in the group with moderate to severe eczema 
(18.3% vs 9.0%, p=0.016) than in the group with mild eczema.  
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Figure 8 shows the proportions with asthma and/or rhinitis among boys and 
girls with no, mild and moderate to severe eczema at the 12-year follow-up. 
Both asthma and rhinitis were more prevalent among boys compared to girls, 
irrespective of eczema status. Of boys with moderate to severe eczema, 
59.0% had asthma, rhinitis or both diseases (Figure 8). 
 
 
Figure 8. Proportion of girls and boys with asthma and/or rhinitis among pre-
adolescent children with no, mild and moderate-to-severe eczema in the BAMSE 
birth cohort. 
 
 
Infantile eczema, comorbidity and prognosis (IV) 
In study IV we found that presence of asthma in infancy among children 
with infantile eczema was associated with asthma in pre-adolescence 
(adjusted OR 5.83; 95% CI 3.46-9.81). Rhinitis before age two among 
children with infantile eczema was associated with eczema (adjusted OR 1.73; 
95% CI 1.10-2.71), asthma (adjusted OR 3.15; 95% CI 1.87-5.29) and rhinitis 
(adjusted OR 2.01; 95% CI 1.30-3.10) in pre-adolescence. Adjustment was 
made for sex and parental allergy.  
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INFANTILE ECZEMA – PROGNOSIS (IV) 
Almost half of the 810 children with infantile eczema in study IV had 
eczema, asthma or rhinitis at the 12-year follow-up (Figure 9). 
 
 
 
Figure 9. Allergy-related disease in pre-adolescence in relation to infantile eczema. 
Subjects of the BAMSE birth cohort included in the study population in paper IV and 
outcome of allergy-related disease at twelve years for children with and without 
infantile eczema. Venn diagrams are proportional. Since some children have more 
than one disease, the numbers add up to more than 100%. 
 
 
Children with infantile eczema had a threefold risk of eczema in pre- 
adolescence (adjusted OR 3.97; 95% CI, 3.18-4.95, adjusted for sex and 
parental allergy) compared with children without eczema before two years of 
age (Figure 10). Children with infantile eczema also had an increased risk of 
asthma, adjusted OR 2.22; 95% CI 1.65-2.98 (adjusted for sex, parental 
allergy and asthma before two years) and rhinitis, adjusted OR 2.69; 95% CI, 
2.22-3.26 (adjusted for sex, parental allergy and rhinitis before two years).  
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To ensure that the increased risk of asthma and rhinitis in pre-adolescence 
among children with infantile eczema was not explained by children who had 
eczema in pre-adolescence with concomitant asthma and rhinitis, we 
restricted the analyses, including only the 606 children with infantile eczema 
who did not have eczema in pre-adolescence. When this was done, the 
adjusted ORs decreased to 2.06; 95% CI 1.89-2.96 for asthma and 2.36; 95% 
CI 1.89-2.96 for rhinitis. 
 
 
 
Figure 10. Increased risk of eczema, asthma, rhinitis and any of the diseases in pre-
adolescence for children with infantile eczema (n=810), in the population-based 
BAMSE birth cohort (n=3,208). All odds ratios (OR) were adjusted for sex and 
parental allergy. In addition, the OR for asthma was adjusted for asthma before 
two years, the OR for rhinitis for rhinitis before two years and the OR for any 
disease for asthma and rhinitis before two years of age. 
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INFANTILE ECZEMA – RISK FACTORS (IV) 
Table VIII shows adjusted ORs for significant risk factors for eczema, 
asthma and rhinitis in pre-adolescence among children with infantile eczema.  
 
Table VIII. Risk factors for allergy-related disease in pre-adolescence for 
children with infantile eczema (n=810) in the BAMSE birth cohort 
Risk factors* (%) before 2 years of age 
among children with infantile eczema  
Eczema at age 12 
205/810 
Adjusted
†
 OR 
(95% CI) 
Asthma at age 12 
93/804 
Adjusted
†
 OR 
(95% CI) 
Rhinitis at age 12 
263/808 
Adjusted
†
 OR 
(95% CI) 
Sex (boys vs. girls) (50.9) 0.77 (0 .56-1.06) 1.62 (1.03-2.53) 1.33 (0 .99-1.80) 
Parental allergy
○
 (54.3) 1.45 (1.05-2.01) 1.96 (1.23-3.13) 1.88 (1.39-2.56) 
Tobacco exposure
▲
 (25.6) 1.42 (1.00-2.03) 1.68 (1.05- 2.69) 1.03 (0.73-1.45) 
Asthma before 2 years of age (10.8) 1.17 (0.70-1.94) 5.83 (3.46-9.81) 1.48 (0.93-2.36) 
Rhinitis before 2 years of age (12.5) 1.73 (1.10-2.71) 3.15 (1.87-5.29) 2.01 (1.30-3.10) 
Sleep disturbance due to itch (28.8) 1.98 (1.41-2.78) 1.84 (1.17- 2.89) 1.65 (1.19-2.28) 
Widespread infantile eczema (13.1) 1.60 (1.02-2.50) 1.23 (0.67-2.25) 2.46 (1.61-3.75) 
Persistent infantile eczema (35.6) 1.94 (1.40-2.69) 2.05 (1.32-3.20) 2.10 (1.54-2.86) 
Atopic infantile eczema
□
 (44.5) 3.10 ( 1.47-6.54)   3.19 (1.20-8.50) 4.32 (2.04-9.12) 
* Internal missing ranged between 0% and 2%. 
† Adjusted for sex and parental allergy. 
○
 Doctor’s diagnosis of asthma and/or hay fever in combination with allergy to furred pets and/or pollen 
and/or doctor’s diagnosis of eczema at enrolment. 
▲
 Mother smoked at least one cigarette per day during pregnancy and/or any of the parents smoked at least 
one cigarette per day at the time of enrolment. 
□
 Defined as allergen-specific IgE ≥ 0.35 kUA/L against foods and/or airborne allergens at age 2 years based 
on data from 137 cases. 
 
 
 
 
Reflection - how to present data 
When we discussed how to present the results in paper IV, I argued for the use of simple 
measures that could be easily understood to describe factors of importance for future 
disease among infants with eczema. We considered the use of sensitivity, specificity, PPV 
(positive predictive value) and NPV (negative predictive value), for risk factors or 
combinations of risk factors in infancy for the outcomes eczema, asthma and rhinitis in 
pre-adolescence. To me this felt intuitively wrong because I associate these measures with 
evaluation of diagnostic tests. However, it is perfectly correct and these measures are also 
frequently used in studies similar to study IV.151 152  In the end we agreed on the use of OR 
and absolute risk. Meanwhile, I realized that absolute risk, which is actually nothing other 
than the simplest risk measure, is calculated in exactly the same way and corresponds to 
PPV.  
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INFANTILE ECZEMA – ABSOLUTE RISKS (IV) 
We also combined different risk factors in infancy and calculated absolute 
risks for eczema, asthma and rhinitis at age twelve. Absolute risks for several 
phenotypes of infantile eczema, as well as for children with no allergy-related 
disease before age two, are presented in Table IX. As expected, children 
without infantile eczema, asthma or rhinitis before age two had the lowest 
risks for all three diseases at age twelve. As shown in Table IX persistent 
infantile eczema was a significant risk factor for both eczema, asthma and 
rhinitis in pre-adolescence. The reference was children with infantile eczema 
only in their first or second year of life. We evaluated these two groups 
separately and found that children with eczema in their first year of life, but 
not in their second year, had half the risk of eczema at age twelve (Table IX) 
compared with children with eczema in their second, but not in their first 
year of life. Despite the marked difference in risk of eczema these two groups 
had similar risks for asthma and rhinitis at age twelve (Table IX). 
 
 
 
 
 
Reflection – word count 
Paper IV contained many sub-group analyses, and was therefore a lengthy article of 3,622 
words, two figures and 7 tables when we submitted it to JACI. The word limit for original 
articles in JACI is a generous 3,500 words. However, I could not find a way to cut 122 
words out of the manuscript and still retain the messages and the data we had agreed to 
present. Therefore, we decided to submit the article as it was. The paper was not accepted 
as a full length article but the Editor gave us a chance to resubmit the paper as a Letter to 
the Editor. This format has a word limit of 1000 words and allows a maximum of two 
figures and tables. At first I thought it impossible: if I had not been able to cut the paper 
by 122 words how could I possibly shorten it 2,622 words? On the other hand, if this was 
the Editor’s suggestion, it was probably doable, so I decided to give it a try. The referees’ 
comments helped me and I was surprised by how easily the manuscript was shortened. 
Making radical changes is sometimes easier than making minor ones. 
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Table IX. Absolute risks for eczema, asthma and rhinitis in pre-
adolescence for various combinations of risk factors up to two years 
(n=3,208)  
 Risk factors up to 2 years of age 
(number of children the 
calculations are based on) 
Absolute risk* 
for eczema 
at 12 years  
%  (95% CI) 
Absolute risk* 
for asthma 
at 12 years  
%  (95% CI) 
Absolute risk* 
for rhinitis  
at 12 years 
%  (95% CI) 
None of the 
diseases 
at 12 years 
 %  (95% CI) 
Among all children (n=3208) 
 No eczema, asthma or rhinitis before 
two years (2086) 7.2 (6.1-8.4) 4.4 (3.6-5.4) 13.3 (11.9-14.9) 78.9 (77.1-80.7) 
Among all children with infantile eczema (IE) (n=810) 
 IE (810) 25.3 (22.3-28.4) 11.6 (9.4-14.0) 32.5 (29.3-35-9) 50.7 (47.2-54.2) 
 IE in the first but not the second 
year of life (203) 12.3 (8.1-17.6) 10.9 (7.0-16.0) 27.2 (21.1-33.9) 63.9 (56.8-70.5) 
 IE in the second but not the first 
year of life (319) 26.3 (21.6-31.5) 6.94 (4.4-10.3) 25.7 (21.0-30.9) 56.0 (50.3-61.5) 
 Persistent IE (288) 33.3 (27.9-39.1) 17.2 (13.0-22.1) 43.9 (38.1-49.9) 35.8 (30.2-41.6) 
 Persistent IE causing sleep 
disturbance (131) 36.6 (28.4-45.5) 21.5 (14.8-29.6) 53.8 (44.9-62.6) 24.4 (17.3-32.7) 
 IE only, no asthma, no rhinitis (642) 24.1 (20.9-27.6) 8.0 (6.0-10.4) 30.3 (26.7-34.0) 53.4 (49.5-57.4) 
 IE and asthma (87) 27.6 (18.5-38.2) 36.8 (26.7-47.8) 42.5 (32.0-53.6) 42.5 (32.0-53.6) 
 IE and rhinitis (100) 36.0 (26.6-46.2) 27.0 (18.6-36.8) 49.5 (39.3-59.7) 31.0 (22.1-41.0) 
 IE and comorbidity† (152) 30.3 (23.1-38.2) 27.6 (20.7-35.5) 43.7 (35.7-52.0) 38.2 (30.4-46.4) 
 IE and asthma and rhinitis (35) 40.0 (23.9-57.9) 48.6 (31.4-66.0) 57.1 (39.4-73.7) 28.6 (14.6-46.3) 
Among children with IE and complete data on sensitization at 2 years of age (n=137) 
 IE without sensitization○ (non-atopic 
IE) (76) 22.4 (13.6-33.4) 10.5 (4.7-19.7) 28.9 (19.1-40.5) 53.9 (42.1-65.5) 
 IE with sensitization○ (atopic IE) 
(61) 45.9 (33.1-59.1) 27.9 (17.1-40.8) 65.0 (51.6-76.9) 23.0 (13.2-35.5) 
Among children with IE and comorbidity† and complete data on sensitization at 2 years of age (n=26) 
 IE with comorbidity† , no 
sensitization○ (9) 33.3 (7.5-70.1) 33.3 (7.5-70.1) 33.3 (7.5-70.1) 22.2 (2.8-60.0) 
 IE with comorbidity† and 
sensitization○  (17) 64.7 (38.3-85.8) 52.9 (27.8-77.0) 75.0 (47.6-92.7) 17.6 (3.8-43.4) 
 IE with comorbidity† and               
sensitization both to foods and 
airborne allergens (8) 75.0 (34.9-96.8) 75.0 (34.9-96.8) 100 (59.0-100)
□
 0 (0-36.9)
□
 
*Absolute risk was calculated as the number of children having both the outcome and the risk factor, divided 
by the total number of children with the risk factor. For 95% confidence intervals, the binomial test of 
statistical significance was used. 
†Comorbidity is defined as any or both of the diseases asthma and rhinitis before age 2.  
○Sensitization is defined as allergen-specific IgE≥0.35 kUA/L to food and/or airborne allergens.  
□
One-sided confidence interval. 
 
 
QUALITY OF LIFE IN PRE-ADOLESCENCE (III) 
A majority of the 2,756 pre-adolescent children included in study III reported 
good self-perceived health. Seventy-nine percent responded “Excellent” or 
“Very good” to the question “How are you feeling?” and 72% reported that they 
were completely healthy, while 66% responded “I am very happy” to the 
question “How happy are you with your life right now?” Of the 350 children with 
eczema in study III, 120 children had ongoing symptoms when they 
answered the 12-year questionnaire.  
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In total, 274 children had mild eczema and 76 had moderate-to-severe 
disease. The proportion of children with moderate-to-severe eczema was 
40.8% in the group with ongoing eczema at the time of the 12-year 
questionnaire and 11.7% among children without ongoing skin symptoms. 
Among children with moderate-to-severe eczema, 88% had had a doctor’s 
diagnosis of eczema at some time up to twelve years of age, compared with 
57% of the children with mild eczema (p=0.001). The impact of eczema, 
asthma and rhinitis on self-perceived health was calculated by using multiple 
logistic regression with adjustment for parental allergy, low socio-economic 
status, having a young mother and comorbidity. Sex was found to be an 
effect modifier and therefore the analysis was stratified by sex. 
 
Self-perceived health among girls (III) 
Girls with eczema had impaired self-perceived health, as evaluated by all 
three questions, compared with girls with no allergy-related disease (Table X). 
We restricted the analyses to include only girls with mild eczema and found 
that they reported significantly impaired self-perceived health for all three 
questions: adjusted OR 1.73 (95% CI 1.14-2.64) for the question “How are you 
feeling? ”, adjusted OR 1.90 (95% CI 1.27-2.86) for the question “How healthy 
do you consider yourself to be?”, and 1.63 (95% CI 1.11-2.40) for the question 
“How happy are you with your life right now?”. Finally, we evaluated the impact of 
asthma and rhinitis for self-perceived health among girls and found these 
diseases to be associated with significantly impaired self-perceived health for 
the question “How healthy do you consider yourself to be?”, but not for the other 
questions (Table X). 
 
 
Reflection – impact factors 
The impact of impact factors in the world of medical research is incredibly large. Even 
though impact factor is a journal metric and should not be used to assess individual 
researchers, this is not how it works. Anyone who strives for a research career should 
acquire a thoughtful approach when it comes to impact factors. I have learned that a short 
article in a high ranked journal is more “valuable” than a long article in a lower ranked 
journal, as long as the article deals with original data. I have also learned that a “Letter to 
the Editor” does not count as a citable format and will therefore not be counted as 
“citable” when the journal’s impact factor is being calculated, but if cited anyway, it can 
contribute to the impact factor of the journal. Thus, publishing articles with original data 
as a “Letter to the Editor” is a tactic a journal might use to raise its impact factor. 
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Self-perceived health among boys (III) 
In contrast to girls, eczema among boys was not associated with impaired 
self-perceived health (Table X). However, as for girls, boys with asthma and 
rhinitis reported significantly impaired self-perceived health for the question 
“How healthy do you consider yourself to be?” (Table X).  
 
Table X.  Adjusted* odds ratios (OR) for impaired self-perceived health 
among pre-adolescent girls (upper section) and boys (lower section) in 
relation to eczema, asthma and rhinitis in the population-based BAMSE 
birth cohort N=2,756 
Question asked How are you 
feeling?  
How healthy do 
you consider 
yourself to be? 
How happy are 
you with your life 
right now? 
Response alternatives Not good/ 
fairly good 
/good vs. 
Excellent/very 
good 
Not very 
healthy/fairly 
healthy vs. 
Completely 
healthy 
I am not happy at 
all / I am not very 
happy / I am 
fairly happy  vs. I 
am very happy 
GIRLS (n=1,375) 
adjusted OR* 
 (95% CI) 
adjusted OR* 
 (95% CI) 
adjusted OR* 
(95% CI) 
No eczema, asthma or rhinitis (n=972) 1 1 1 
Eczema (n=210) 1.72 (1.16-2.55) 1.89 (1.29-2.76) 1.69 (1.18-2.42) 
Subgroup with ongoing eczema (n=80) 2.32 (1.26-4.27) 2.44 (1.34-4.43) 3.20 (1.72-5.95) 
Mild eczema (n=171) 1.73 (1.14-2.64) 1.90 (1.27-2.86) 1.63 (1.11-2.40) 
Moderate to severe eczema (n=39) 1.79 (0.70-4.58) 1.84 (0.74-4.56) 2.14 (0.88-5.19) 
Asthma (n=68) 1.18 (0.48-2.86) 2.79 (1.30-6.00) 0.57 (0.24-1.35) 
Rhinitis (n=228) 1.05 (0.68-1.61) 1.78 (1.22-2.59) 1.20 (0.84-1.73) 
Eczema, asthma and rhinitis (n=16) 1.85 (0.63-5.44) 3.72 (1.35-10.2) 1.74 (0.64-4.73) 
BOYS (n=1,381) 
adjusted OR* 
(95% CI) 
adjusted OR* 
(95% CI) 
adjusted OR* 
(95% CI) 
No eczema, asthma or rhinitis (n=951) 1 1 1 
Eczema (n=140) 0.78 (0.40-1.52) 0.70 (0.38-1.29) 0.73 (0.41-1.27) 
Subgroup with ongoing eczema (n=40) 0.94 (0.26-3.41) 0.88 (0.28-2.76) 0.62 (0.19-1.98) 
Mild eczema (n=103) 0.68 (0.31-1.50) 0.51 (0.24-1.10) 0.66 (0.34-1.26) 
Moderate to severe eczema (n=37) 1.26 (0.39-4.10) 1.53 (0.55-4.25) 0.94 (0.32-2.70) 
Asthma (n=116) 1.17 (0.57-2.42) 1.97 (1.06-3.64) 0.83 (0.43-1.62) 
Rhinitis (n=300) 1.42 (0.98-2.07) 2.31 (1.67-3.19) 1.00 (0.71-1.40) 
Eczema, asthma and rhinitis (n=23) 7.84 (3.32-18.5) 6.37 (2.66-15.3) 1.60 (0.68-3.75) 
*Adjusted for parental allergy, low socio-economic status, having a young mother and comorbidity 
(eczema, asthma and rhinitis at the 12-year follow-up). 
Statistically significant differences are written in bold. 
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Disease-specific HRQoL (III) 
The mean total score of CDLQI for all children with eczema was 3.98 (95% 
CI 3.37-4.58). Children with moderate-to-severe eczema reported a total 
score of 5.12 (95% CI 4.21-6.04), compared with 3.18 (95% CI 2.42-3.95) for 
children with mild eczema. Ninety-five percent of the 120 children with 
ongoing eczema reported that they were troubled by itching and scratching. 
Other questions with high scores among both boys and girls were the 
questions about i) being embarrassed or upset because of skin symptoms, ii) 
trouble with treatment and iii) disturbed sleep. There was a significant 
correlation (r=0.493) between CDLQI scores and eczema severity as well as 
between CDLQI scores and health impact as assessed in the three questions 
on self-perceived health, all p <0.05. 
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10 DISCUSSION 
STRENGTHS AND LIMITATIONS 
The major strength of this thesis is the population-based study design and 
that data were collected prospectively. The comparatively large number of 
participants and limited loss to follow-up enables subgroup analysis and 
allows for stratified analysis in many cases. Furthermore, assessment of 
exposures, eczema, asthma and rhinitis, on five occasions during the first 12 
years of life, reduces the risk of recall bias. A weakness of the study is that 
information on outcomes was obtained from questionnaires only.  
 
 
METHODOLOGICAL CONSIDERATIONS 
Both random and systematic errors are likely to occur in observational studies 
and might possibly affect the precision, internal validity and generalizability of 
the results. It is important to consider these possible errors throughout the 
whole research process, from deciding what study design to choose and how 
many subjects to include, later on when one performs the analysis and finally 
when one interprets the results. 
 
Random error 
The relatively large study populations and the fact that the diseases studied in 
this thesis are all common have contributed to minimizing random errors. 
Confidence intervals were computed in all papers to demonstrate the 
precision of estimates. In general, the confidence intervals are rather narrow, 
indicating good precision. However, for some subgroup analyses in paper IV 
estimating absolute risk, the statistical uncertainty is large. 
 
Systematic error – selection bias 
Selection bias in this thesis might have occurred at three stages. First, when 
the BAMSE cohort was recruited, second when children were lost to follow-
up, and third when the study populations were selected. At recruitment 75% 
of the eligible children were included. A survey of the non-
responders/excluded group showed that parental smoking was more 
prevalent in non-participating families, but otherwise no significant 
differences concerning parental allergy and other known risk factors for 
allergy-related diseases were found.13  
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To evaluate possible selection bias due to loss to follow-up and selection of 
study populations the study populations were compared to the original 
cohort for: i) background factors that have been shown to be associated with 
the outcomes (papers I (see Table V), III, IV), and ii) allergy-related diseases 
(papers I (see Table VI), IV). No significant differences were found. Taken 
together, this indicates that the study populations used in this thesis are less 
exposed to parental smoking but seem otherwise to be comparable to the 
source population. Thus, selection bias is probably of minor importance, but 
might have led to a small underestimation of allergy-related disease since 
parental smoking has been shown to be a risk factor for allergy-related 
diseases.141 153 
 
 
 
Reflection – which families came to all follow-ups? 
When doing the analysis for paper I, I was very surprised to find that 58% of children had 
had an allergy-related disease before adolescence. I first figured that I had made some 
mistake in my syntax for the calculations, but that was not the case. My second thought 
was that it must be a result of selection bias. In study I, we had selected only the children 
who had participated at all five follow-ups. When looking at the high numbers I felt 
convinced that by doing so we had selected the families with children who had allergy-
related diseases, who probably had an extra motivation to participate. However, as shown 
in table VI we found no significant differences and rather a tendency of higher rates of 
allergy-related diseases among children who had not participated at all follow-ups. The 
same phenomenon has been described in the ALPSAC and PIAMA studies.154 Thus, the 
presence of allergy-related disease does not appear to bias the decision to participate at 
each follow-up in a positive direction. 
 
 
 
Systematic error – information bias  
Information bias due to recall bias has been minimized by the prospective 
study design with collection of background information before development 
of disease and with assessment of exposures, eczema, asthma and rhinitis, on 
five occasions during the first 12 years of life. Misclassification of disease is 
bound to have occurred for all diseases in all studies presented in this thesis. 
How diseases are defined is critical in order to minimize misclassification. A 
strict definition will exclude milder cases while an inclusive definition risks 
classifying healthy children as having disease.  
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The gold standard for assigning a diagnosis of eczema, asthma and rhinitis is 
that the patient has been evaluated and diagnosed by a physician. In this 
thesis, however, all diseases are classified based on parentally reported 
symptoms and parentally reported doctor’s diagnosis. If reported doctor’s 
diagnosis of disease had been used as the sole measure of disease, prevalence 
rates (especially for eczema and rhinitis) would probably have been 
underestimated since treatment is available over the counter and mild cases 
do not always prompt contact with the health care system. Moreover, these 
diseases are fluctuant by nature and even physicians often base their diagnosis 
on parentally reported symptoms.  
 
The eczema definition used in BAMSE has been validated in children up to 2 
years and was found to have high sensitivity (92%) and specificity (100%) in 
relation to clinical diagnosis by a dermatologist,155 indicating that 
misclassification of eczema in young children is limited. The eczema variable 
used in this thesis has not been evaluated in older children but data from the 
16-year follow-up that include both a validated eczema severity score 
(POEM)100 and clinical evaluation of children with eczema by a nurse 
specialized in paediatric dermatology will provide an estimate of the reliability 
of the eczema definition in older children. 
 
Misclassification – possible consequences 
The definition used for rhinitis at age 1 and 2 years in study I was prolonged 
rhinitis > 2 months. Since the questionnaires did not include any question on 
the association with common cold, the prevalence rates of rhinitis at age 1 
and 2 have probably been overestimated. In contrast, the asthma definition 
used in all papers for all ages is rather strict and milder cases have probably 
not been included, which could explain the rather low prevalence rates 
presented in paper I. Another consequence might be that turnover of asthma 
was overestimated while persistence of asthma was underestimated in study I.  
 
Individuals who are in contact with the health care system for one disease are 
more likely to be diagnosed with, or medicated for, another disease, especially 
when it comes to known comorbidities. This phenomenon, called “biased 
follow-up”, could possibly have affected the results in study II since a larger 
proportion of children with moderate-to-severe eczema had a doctor’s 
diagnosis of eczema compared to children with mild eczema.  
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However, children were classified with asthma and rhinitis mainly based on 
reported symptoms and in addition a majority of children both with mild and 
moderate-to-severe eczema had a doctor’s diagnosis of eczema. Thus, taking 
all this together, I do not expect misclassification to have influenced the 
results of study II. Apart from the types of misclassification mentioned 
above, misclassification of disease is most likely non-differential and might 
have diluted the associations found both in study III and study IV.  
 
Systematic error – confounding 
Confounding was in part dealt with in this thesis by the BAMSE study design 
itself. By including the study subjects at birth and arranging for follow-ups at 
specific time-points, age as a confounder was controlled for. In addition, 
collection of detailed information on background factors and allergy-related 
diseases enabled adjustment for several potential confounders. In study I and 
in the thesis summary, we used generalized estimated equations when 
assessing the impact of parental allergy and sex on development of any 
allergy-related disease and eczema, thus controlling for confounding. In study 
III and IV multivariate regression models were used, making it possible to 
adjust for several confounders. As in all non-randomized studies, influence of 
unknown or unmeasured factors (residual confounders) cannot be excluded.  
 
Generalizability 
In all papers included in this thesis the population-based design has been 
emphasised as a strength and a major concern is therefore whether the results 
are valid even in other populations. Given the limited selection bias described 
above, the relatively good precision, and how the source population was 
selected, it is plausible to assume that the results can be generalized to 
paediatric populations in other high-income and urban-industrial settings 
with comparable rates of allergy-related diseases and background factors. 
 
 
MAIN FINDINGS 
Prevalence rates (I) 
One of the most striking findings in this thesis was the high prevalence rates 
of allergy-related diseases. As many as 38% had had eczema and in total 58% 
in the population-based birth cohort had had an allergy-related disease before 
adolescence.  
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A valid concern is whether these figures are overestimated. As argued in the 
previous section, these findings can probably not be explained by 
methodological errors. The fact that the prevalence rates of eczema and 
rhinitis at each follow-up are comparable to, and those of asthma somewhat 
lower than, the rates reported by others 17 23 33 49 52 150 156 157 speaks against an 
overestimation. The overall prevalence rates for allergy-related diseases found 
in our study are comparable to those in the Isle of Wight birth cohort study, 
where children were evaluated yearly up to the age of 4 years. In that study 
40% of the children had had an allergy-related disease at some time before 
reaching 4 years of age.158 In our study the corresponding proportion was 
45%. Moreover, a recent publication from a Danish population-based study 
with regular follow-ups from childhood until age 26 years found that more 
than half of the study participants had had an allergy-related disease.159 In 
addition, a population-based study from northern Sweden, with a 
participation rate of 97%, including 4,331 seven to eight years old children 
found the reported lifetime prevalence of eczema to be 35%160 which can be 
compared to the 38% found among pre-adolescents in our study. 
 
Comorbidity of allergy-related diseases (I) 
In study I we could show that comorbidity between eczema, asthma and 
rhinitis became more prevalent with increasing age and among 12-year-olds 
7.5% have two or three of the diseases. This is in line with the findings from 
the ISAAC study where the corresponding proportion among 13-14-year-old 
children in Sweden was 6-<9%.14 A recent publication from Rönmark and 
co-authors investigating eczema and allergy-related diseases in adults from a 
population-based setting in West Sweden showed that the proportion of 
adults having two or three of the diseases eczema, asthma and rhinitis was 
7.8%.161 Thus, it seems that the high degree of comorbidity persists into 
adulthood. 
 
Prognosis of infantile eczema (IV) 
We were glad to find that half of the children with infantile eczema were free 
of allergy-related disease in pre-adolescence and that only 25% had eczema. 
The prognosis of eczema in our study is better than previously described19 118 
162 163 which probably has to do with the population-based design, which 
allowed us to include even the mildest cases of infantile eczema.  
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Thus, the rather good prognosis is important to bear in mind when 
discussing public health issues and can be used to comfort the parents of 
infants with eczema visiting healthcare clinics. However, the prognosis is 
probably not equally positive for children with infantile eczema attending 
specialist clinics.   
 
Eczema in relation to asthma and rhinitis (II, IV) 
The risk that children with infantile eczema will develop asthma has been 
thoroughly investigated and the adjusted OR of 2.2 for asthma at 12 years 
found in study IV is comparable to what has been shown by others, even 
though most studies have examined the risk at earlier ages than twelve years.19 
29 164 165 In recent years there has been an increased interest in the relation 
between eczema and rhinitis and studies evaluating rhinitis in relation to 
eczema have shown strong associations between the two diseases.23 121 166 This 
strong association has been further highlighted by the findings in this thesis. 
In study II we showed that rhinitis is associated with severity of eczema: the 
risk of rhinitis is higher among pre-adolescents with moderate to severe 
eczema compared to those with mild eczema. Furthermore, in study IV we 
could show that comorbidity of rhinitis among children with infantile eczema 
is associated to a worse prognosis for eczema but also with an increased risk 
of asthma and rhinitis in pre-adolescence.  
 
However, we did not find concomitant asthma among infants with eczema to 
worsen the prognosis of eczema. This finding confirms the result from Ricci 
and co-workers, who studied a selected cohort of children with eczema, aged 
6-36 months.167 In contrast, a recent study from a selected cohort of older 
children with eczema (2-18 years) found a strong correlation between 
concomitant asthma and more persistent eczema.168 This discrepancy might 
be explained by the different age-groups examined. Asthma in older children 
is often associated with atopy which in our study was strongly associated with 
poor prognosis for eczema, whereas wheeze and asthma in infancy has been 
suggested to be triggered mainly by upper airway infections.169     
 
In contrast to findings from the MAS-study by Illi and co-workers19 the 
increased risk of both asthma and rhinitis among children with infantile 
eczema in study IV remained significant after adjustment for early asthma 
and rhinitis. Furthermore, these increased risks remained significant even 
after exclusion of children with eczema at age twelve.  
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Infantile eczema in the first year of life only (IV) 
One of the most interesting results of this thesis was that infants with eczema 
during their first, but not their second year of life, have almost half the risk of 
eczema at 12 years, but the same risk of asthma and rhinitis as compared with 
other infants with eczema. There is one brief report by Vickers from 1980 
including 2000 English children with eczema from a population-based setting 
that is suggestive of poorer prognosis of eczema among children with onset 
between 12 and 24 months as compared with children with earlier onset.170  
 
However, our finding is in contrast to the general view that early onset is 
associated with worse prognosis,111 a perception that has some support in the 
literature162 163 171 and also holds true for the children in our study with onset 
in the first year of life, who continued having eczema in their second year of 
life. Illi and co-workers followed 241 children with infantile eczema from a 
population-based cohort up to the age of 7 years in the MAS-study. They 
found no difference in prognosis of eczema when comparing children with 
onset of eczema in the first year of life to children with onset in their second 
year of life.19 However, in that study, children with infantile eczema in both 
their first and second years of life were analysed together with children with 
eczema in their first, but not in their second year of life.  
 
Quality of life among pre-adolescents with eczema (III) 
We found that eczema was associated with impaired self-perceived health 
both in girls with mild eczema and in girls with more severe disease. Eczema 
among boys was not associated with impaired self-perceived health. Even 
though a majority of children with eczema reported that they were 
completely healthy and very happy with life, the finding that eczema among 
girls impairs self-perceived health is important. Since eczema affects up to 
20% of pre-adolescent girls53 and adolescence is a critical time for the 
development of self-identity and self-esteem172 we believe that the findings 
have implications for health care providers as well as for society as a whole.  
 
From disease-specific instruments we know that impaired HRQoL among 
people with eczema is due to itching, sleep deprivation and embarrassment 
caused by skin symptoms.5 129  However, it is hard to believe that these 
factors are the entire explanation in the group of girls with mild disease, 
among whom a majority did not have ongoing eczema when they answered 
the questionnaire.  
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CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVE 
The large number of new and remitting cases found in study I for allergy-
related diseases during childhood raises the question of when an outcome 
should be evaluated in relation to risk factors being studied. The results from 
study I might be of value in studies addressing risk factors for development 
of allergy-related diseases when deciding on what time period to use for 
evaluation of outcomes.  
 
In study II we showed that prevalence of rhinitis and asthma is associated 
with eczema severity, with the highest prevalence among boys with moderate 
to severe eczema. For physicians who take care of children with eczema this 
is important knowledge. Eczema is a troublesome and visible disease and 
children and their parents notice the disease. In contrast, the symptoms of 
asthma and sometimes also rhinitis are more insidious and may sometimes be 
overlooked by children and parents, especially if the children are tired due to 
sleep deprivation caused by an itching eczema. Thus, based on our findings I 
believe that a child, and in particular a boy, who seeks advice for troublesome 
eczema should be asked about symptoms of both asthma and rhinitis so that 
comorbidities can be discovered and treated. 
 
In view of the finding that eczema among pre-adolescent girls affects self-
perceived health, it would be interesting to conduct a qualitative study with 
the aim of disentangling what these girls with very mild disease are troubled 
by. Is it the disease itself, the treatment required or other factors? Findings 
from such a study could possibly be used to improve management of eczema 
for this age-group.  
 
Even though disputed, the concept of the atopic march is used to describe 
the sequential onset of allergy-related diseases in childhood, starting with 
eczema followed by asthma and rhinitis. The findings of study IV that 
infantile eczema is a risk factor for asthma and rhinitis in pre-adolescence, 
independent of asthma and rhinitis in infancy and of eczema in pre-
adolescence, speaks in favour of the existence of the atopic march.  
 
Furthermore, our findings in study IV confirm that atopy among children 
with infantile eczema is strongly associated with future risk of asthma and 
rhinitis. However, children with non-atopic eczema as evidenced by testing at 
age 2 years also had elevated absolute risks of asthma and rhinitis in pre-
adolescence as compared to children without allergy-related diseases in 
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infancy. There is emerging evidence of the fluctuant nature of sensitization in 
childhood159 173 and it is possible that these children are truly atopic but that 
the sensitization was present at another age. To test this possibility it would 
be interesting to explore whether the increased risk for asthma or rhinitis 
among children with eczema is driven solely by an atopic constitution or 
whether a non-atopic march from eczema to asthma and rhinitis exists. 
 
We found that children with eczema in their first but not in their second year 
of life have the same risk for asthma and rhinitis in pre-adolescence as other 
children with infantile eczema. Unexpectedly, we found that these children 
(with infantile eczema in their first year of life only) have a markedly better 
prognosis for eczema. It is important to find out whether this finding is 
replicable. If so, one explanation could be that these children represent a 
particular phenotype. Another explanation could be that treatment of 
eczema, or some other exposure in the first year of life, alters the risk of 
subsequent eczema but not the risk of asthma or rhinitis. If such an exposure 
exists, it is important to identify it in future studies, as it might possibly 
influence the clinical course of eczema in childhood. 
 
It has been suggested that impaired skin barrier function, represented by 
eczema in early life, may act as a catalyst for IgE sensitization and subsequent 
development of asthma and rhinitis.174 The close relation between eczema in 
infancy and asthma and rhinitis later in life found in this thesis emphasises 
the need for further studies. A major task for the research community is to 
explore whether the association of eczema in early life with asthma and 
rhinitis later in life is merely a consequence of a genetic pre-disposition for 
the three diseases, or alternatively, if presence of eczema and a disrupted skin 
barrier constitute a step in the causal pathway in the development of asthma 
and rhinitis. Accordingly, the most important issue to resolve is whether 
development of asthma and rhinitis might be prevented by early treatment of 
eczema. 
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Reflection – eczema now and then 
When reading the work of colleagues that were active before the discovery of T-cells, skin 
barrier defects, IgE and Filaggrin I find it striking how little impact these findings have had 
for the management of patients with eczema and to some extent also for what we consider 
important in studying the disease. Any clinician managing children with eczema can 
probably recognize their own reality in some of the following quotes from scientific papers 
from another time. I’m impressed by these physicians, the extent of their understanding 
and how they managed to describe what they knew or suspected without having the 
knowledge we today consider fundamental for the understanding of eczema and allergy-
related diseases. The first quote, dated 1935, is in my opinion a good and adequate 
description of my own approach to severe cases of eczema in my daily practice. 
 
Hill and Sulzberger, Archives of Dermatology and Syphilology, 1935 
“Until there is a better understanding of the fundamental variation from the normal which makes atopic 
sensitization possible and until this variation can be directly controlled, the best method of attack in the 
treatment of atopic dermatitis is symptomatic but rational local and systemic therapy plus the determination 
of specific sensitivities and withdrawal of the corresponding atopens from the diet or environment – or an 
attempt at hyposensitization in a few selected cases. The results of these procedures, while sometimes 
encouraging, are by no means ideal.” 175 
 
Volwes et al. British Journal of Dermatology, 1955 
“Obviously there are many degrees of severity of infantile eczema, from the mildest to the most severe; we 
believe, though we have no statistical proof, that as a rough guide, in a series of infants the prognosis is 
progressively better as the severity of eczema is less.” 176 
 
“An attempt to assess psychological factors in the patients and the family was made, but it proved so 
difficult that it was regretfully abandoned.” 176 
 
Meenan, Irish Journal of Medical Science 1959 
“The asthma-eczema syndrome is a common problem. Our present methods of treating infantile eczema are, 
to say the least of it, not very effective. All we can do is to offer soothing creams to an irritable child and 
soothing words to a harassed parent.” 177 
 
“They (the parents, my comment) are prepared to endure sleepless nights listening to the sound of 
steady scratching from the next room, if they can believe that the skin will eventually clear up. It is, 
therefore, important to know what the natural history of infantile eczema is; when and if, the eczema will 
disappear, and what are the chances of the child developing asthma.” 177 
 
“The complex immunobiochemical processes which make up the eczema-asthma syndrome require much 
more study. There is in Boston a society known as the Wheeze, Sneeze and Itch. It is through such societies 
where the allergist, paediatrician and dermatologist can pool their knowledge that advances in the 
management of this distressing complaint will come” 177 
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11 CONCLUSIONS 
The results of this thesis stress the importance of allergy-related diseases and 
in particular eczema as a public health concern among children. Taken 
together, the findings also illustrate the strong relationships between eczema, 
asthma and rhinitis in childhood and show the importance of considering 
comorbidities between these diseases both in research and in clinical practice.  
 
From the separate studies the following conclusions can be drawn:   
 
 Allergy-related diseases affect a majority of the paediatric population 
during the first 12 years of life and the development of eczema, 
asthma and rhinitis is a dynamic process: both new cases and 
remission are common throughout childhood. 
 
 Presence of asthma and rhinitis is associated with eczema severity in 
pre-adolescence, with the highest prevalence among boys with 
moderate to severe eczema. 
 
 Eczema and even mild eczema among pre-adolescent girls is 
associated with impaired self-perceived health. 
 
 Almost half of all children with infantile eczema will have eczema, 
asthma or rhinitis in pre-adolescence, but in three out of four the 
eczema will have remitted.  
 
 Eczema in the first but not the second year of life is associated with 
good prognosis for eczema, but with increased risk of asthma and 
rhinitis in pre-adolescence. 
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12 SVENSK  SAMMANFATTNING 
Bakgrund 
Eksem (böjveckseksem) är en kliande kronisk hudsjukdom som vanligtvis 
startar i barndomen. Tillsammans med astma och rinit räknas eksem till 
gruppen allergisjukdomar. Dessa sjukdomar blir allt vanligare och cirka en 
tredjedel av världens befolkning beräknas ha någon av dessa sjukdomar. 
Eksem kan ge försämrad livskvalitet samt ökar risken för astma och rinit.  
 
Syfte 
Det övergripande syftet med denna avhandling har varit att öka kunskapen 
och förståelsen av eksem i barndomen med särskilt fokus på hur det ser ut på 
befolkningsnivå och på eksemsjukdomen i relation till astma och rinit. 
 
Metod 
Studierna i denna epidemiologiska avhandling är gjorda med material från en 
populationsbaserad födelsekohort bestående av 4089 barn födda i norra 
Stockholm under åren 1994-1996. I BAMSE-studien har barnen därefter 
följts med upprepade frågeformulär och undersökningar till 16 års ålder med 
syfte att undersöka riskfaktorer för utveckling av allergisjukdom. I denna 
avhandling används enkätdata från 0, 1, 2, 4, 8 och 12 års ålder. Vid 12 års 
ålder svarade 82% av familjerna på enkätfrågor. DNA analyserades hos 1854 
barn i blodprov som togs vid 4-års ålder och förekomsten av allergi-
antikroppar (IgE) i serum undersöktes vid 2 års ålder hos 137 barn med 
infantilt eksem.  
 
Resultat 
Avhandlingen visade att mer än var tredje barn hade eksem någon gång 
under uppväxten och att 58% av barnen i befolkningen hade någon av 
sjukdomarna eksem, astma eller rinit innan 12 års ålder. Samsjukligheten 
mellan dessa sjukdomar ökade med stigande ålder och 7,5% av 12-åringar 
hade två eller tre av sjukdomarna eksem, astma och rinit. Eksem ökade risken 
att ha astma och rinit och 12-åringar med medelsvårt till svårt eksem hade 
oftare astma och rinit jämfört med de som hade ett lindrigt eksem. Bland 12-
åriga pojkar med medelsvårt till svårt eksem hade 59% någon av sjukdomarna 
astma och rinit jämfört med 40% bland flickorna. Vi fann att mutation i 
filaggringenen var associerad till förekomst av eksem, men inte till eksemets 
svårighetsgrad.  
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Eksem hos 12-åriga flickor var associerat till en negativ påverkan på 
självupplevd hälsa. Denna påverkan sågs även hos gruppen flickor med 
lindrigt eksem och kunde inte förklaras av samsjuklighet med astma eller rinit. 
Eksem hos pojkar i samma ålder påverkade inte den självupplevda hälsan.  
 
Bland barn med eksem innan 2 års ålder (dvs infantilt eksem) hade hälften 
eksem, astma eller rinit vid 12 års ålder men hos tre av fyra barn hade 
eksemet försvunnit. Hos barn med infantilt eksem var förekomst av 
allergiantikroppar vid 2 års ålder, ärftlighet för allergisjukdom, exponering för 
tobaksrök tidigt i livet, rinit innan 2 års ålder och svårt infantilt eksem 
riskfaktorer för utveckling av allergirelaterade sjukdomar i tonåren. Hos barn 
med infantilt eksem enbart under sitt första levnadsår hade eksemet en god 
prognos. Dock hade dessa barn, i likhet med andra barn med eksem innan 2 
års ålder, en ökad risk att utveckla astma och rinit.    
 
Slutsats 
Resultaten från denna avhandling har bidragit till att öka kunskapen och 
förståelsen gällande eksem hos barn. Avhandlingen visar att eksem, astma 
och rinit bland barn är ett folkhälsoproblem. En viktig lärdom från studierna 
i avhandlingen är att eksem, astma och rinit är sjukdomar som i hög grad är 
relaterade till varandra. Denna kunskap är viktig både för forskare som 
studerar dessa sjukdomar och för läkare och annan sjukvårdspersonal som 
träffar barn med eksem, astma eller rinit.    
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